Impact NN O
of IN O
gain-of-function NN B-PosReg
mutations NNS B-Var
in IN O
the DT O
low-density JJ O
lipoprotein NN O
receptor-related NN O
protein NN O
5 CD O
( -LRB- O
LRP5 NNP B-Gene
) -RRB- O
on IN O
glucose NN B-MPA
and CC I-MPA
lipid NN I-MPA
homeostasis NN I-MPA
. . O

LRP5 NNP B-Gene
loss-of-function NN B-NegReg
mutations NNS B-Var
have VBP O
been VBN O
shown VBN O
to TO O
cause VB O
profound JJ B-MPA
osteoporosis NN I-MPA
and CC O
have VBP O
been VBN O
associated VBN O
with IN O
impaired JJ B-MPA
insulin NN I-MPA
sensitivity NN I-MPA
and CC O
dysregulated VBN B-MPA
lipid NN I-MPA
metabolism NN I-MPA
. . O

We PRP O
hypothesized VBD O
that IN O
gain-of-function NN O
mutations NNS O
in IN O
LRP5 NNP O
would MD O
also RB O
affect VB O
these DT O
parameters NNS O
. . O

We PRP O
therefore RB O
studied VBD O
individuals NNS O
with IN O
LRP5 NNP B-Gene
gain-of-function NN B-PosReg
mutations NNS B-Var
exhibiting VBG O
high JJ O
bone NN O
mass NN O
( -LRB- O
HBM NNP O
) -RRB- O
phenotypes NNS O
and CC O
found VBD O
that IN O
while IN O
there EX O
was VBD O
no DT O
detected VBN O
change NN O
in IN O
insulin NN O
sensitivity NN O
, , O
there EX O
was VBD O
a DT O
significant JJ O
reduction NN B-NegReg
in IN O
serum NN B-MPA
LDL NNP I-MPA
. . O

INTRODUCTION NN O
: : O
Wnt NN O
signaling VBG O
through IN O
LRP5 NNP O
represents VBZ O
a DT O
newly RB O
appreciated VBN O
metabolic JJ O
pathway NN O
, , O
which WDT O
potentially RB O
represents VBZ O
a DT O
target NN O
for IN O
drug NN O
discovery NN O
in IN O
type NN O
2 CD O
diabetes NNS O
and CC O
hyperlipidemia NN O
. . O

Studies NNS O
in IN O
animal NN O
models NNS O
suggest VBP O
a DT O
physiologic JJ O
link NN O
between IN O
LRP5 NNP O
and CC O
glucose NN O
and CC O
lipid NN O
homeostasis NN O
; : O
however RB O
, , O
whether IN O
it PRP O
plays VBZ O
a DT O
similar JJ O
role NN O
in IN O
humans NNS O
is VBZ O
unclear JJ O
. . O

As IN O
current JJ O
literature NN O
links VBZ O
loss-of-function NN O
LRP5 NNP O
to IN O
impaired VBN O
glucose NN O
and CC O
lipid NN O
metabolism NN O
, , O
we PRP O
hypothesized VBD O
that IN O
individuals NNS O
with IN O
an DT O
HBM-causing NNP O
mutation NN O
in IN O
LRP5 NNP O
would MD O
exhibit VB O
improved VBN O
glucose NN O
and CC O
lipid NN O
homeostasis NN O
. . O

Since IN O
studies NNS O
in IN O
animal NN O
models NNS O
have VBP O
suggested VBN O
that IN O
Wnt NNP O
signaling VBG O
augments NNS O
insulin NN O
secretion NN O
, , O
we PRP O
also RB O
examined VBD O
the DT O
effect NN O
of IN O
Wnt NNP O
signaling VBG O
on IN O
glucose-stimulated NN O
insulin NN O
secretion NN O
on IN O
human JJ O
pancreatic JJ O
islets NNS O
. . O

METHODS NNS O
: : O
This DT O
was VBD O
a DT O
matched VBN O
case-control NN O
study NN O
. . O

We PRP O
used VBD O
several JJ O
methods NNS O
to TO O
assess VB O
glucose NN O
and CC O
lipid NN O
metabolism NN O
in IN O
11 CD O
individuals NNS O
with IN O
HBM-causing NNP O
mutations NNS O
in IN O
LRP5 NNP O
. . O

Affected VBN O
study NN O
participants NNS O
were VBD O
recruited VBN O
from IN O
previously RB O
identified VBN O
kindreds NNS O
with IN O
HBM-causing NNP O
LRP5 NN O
mutations NNS O
and CC O
included VBD O
9 CD O
males NNS O
and CC O
2 CD O
females NNS O
. . O

Two CD O
subjects NNS O
that WDT O
were VBD O
being VBG O
treated VBN O
with IN O
insulin NN O
for IN O
type NN O
2 CD O
diabetes NNS O
were VBD O
excluded VBN O
from IN O
our PRP$ O
analysis NN O
, , O
as IN O
this DT O
would MD O
have VB O
obscured VBN O
our PRP$ O
ability NN O
to TO O
determine VB O
the DT O
impact NN O
of IN O
gain-of-function NN O
LRP5 NNP O
mutations NNS O
on IN O
glucose NN O
metabolism NN O
. . O

The DT O
mean JJ O
age NN O
of IN O
the DT O
evaluated VBN O
study NN O
subjects NNS O
was VBD O
55 CD O
7 CD O
with IN O
a DT O
mean JJ O
BMI NNP O
of IN O
27.2 CD O
2.0 CD O
. . O

Control NN O
subjects NNS O
were VBD O
matched VBN O
and CC O
recruited VBN O
from IN O
the DT O
general JJ O
community NN O
at IN O
an DT O
equivalent JJ O
ratio NN O
, , O
with IN O
18 CD O
males NNS O
and CC O
4 CD O
females NNS O
( -LRB- O
mean VB O
age NN O
56 CD O
4 CD O
; : O
mean VB O
BMI NNP O
27.2 CD O
1.0 CD O
) -RRB- O
. . O

Study NN O
testing NN O
was VBD O
conducted VBN O
at IN O
an DT O
academic JJ O
medical JJ O
center NN O
. . O

RESULTS NNS O
: : O
There EX O
were VBD O
no DT O
statistically RB O
significant JJ O
differences NNS O
between IN O
affected JJ O
and CC O
matched VBN O
control NN O
populations NNS O
for IN O
HbA1c NNP O
( -LRB- O
p FW O
= SYM O
0.06 CD O
) -RRB- O
, , O
eAG NN O
( -LRB- O
p FW O
= SYM O
0.06 CD O
) -RRB- O
, , O
insulin NN O
( -LRB- O
p FW O
= SYM O
0.82 CD O
) -RRB- O
, , O
HOMA-B NNP O
( -LRB- O
p FW O
= SYM O
0.34 CD O
) -RRB- O
, , O
or CC O
HOMA-IR NNP O
( -LRB- O
p FW O
= SYM O
0.66 CD O
) -RRB- O
. . O

The DT O
mean JJ O
Insulin NNP O
Sensitivity NNP O
Index NNP O
( -LRB- O
ISI NNP O
) -RRB- O
was VBD O
also RB O
similar JJ O
between IN O
control NN O
and CC O
affected VBN O
individuals NNS O
. . O

Total JJ O
cholesterol NN O
( -LRB- O
p FW O
= SYM O
0.43 CD O
) -RRB- O
, , O
triglycerides NNS O
( -LRB- O
TG NNP O
) -RRB- O
( -LRB- O
p FW O
= SYM O
0.56 CD O
) -RRB- O
, , O
and CC O
HDL NNP O
( -LRB- O
p FW O
= SYM O
0.32 CD O
) -RRB- O
were VBD O
not RB O
different JJ O
between IN O
the DT O
same JJ O
two CD O
groups NNS O
. . O

In IN O
a DT O
small JJ O
subset NN O
of IN O
studied JJ O
subjects NNS O
, , O
intramyocellular JJ O
and CC O
hepatic JJ O
lipid NN O
content NN O
were VBD O
similar JJ O
in IN O
the DT O
affected VBN O
individuals NNS O
and CC O
controls NNS O
when WRB O
quantified VBN O
by IN O
proton NN O
magnetic JJ O
resonance NN O
spectroscopy NN O
( -LRB- O
MRS NNP O
) -RRB- O
. . O

However RB O
, , O
the DT O
mean JJ O
value NN O
for IN O
serum NN O
LDL NNP O
was VBD O
significantly RB O
lower JJR O
( -LRB- O
p FW O
= SYM O
0.04 CD O
) -RRB- O
in IN O
affected VBN O
individuals NNS O
. . O

In IN O
primary JJ O
human JJ O
islets NNS O
, , O
there EX O
were VBD O
no DT O
differences NNS O
between IN O
control NN O
and CC O
Wnt NNP O
treatment NN O
groups NNS O
for IN O
insulin NN O
secretion NN O
measured VBN O
as IN O
area NN O
under IN O
the DT O
curve NN O
( -LRB- O
AUC NNP O
) -RRB- O
for IN O
first JJ O
phase NN O
( -LRB- O
p FW O
= SYM O
0.17 CD O
) -RRB- O
or CC O
second JJ O
phase NN O
( -LRB- O
p FW O
= SYM O
0.33 CD O
) -RRB- O
insulin NN O
secretion NN O
. . O

CONCLUSIONS NNS O
: : O
Although IN O
our PRP$ O
sample NN O
size NN O
was VBD O
small JJ O
, , O
our PRP$ O
data NNS O
do VBP O
not RB O
support VB O
the DT O
hypothesis NN O
that WDT O
HBM-causing NNP O
LRP5 NN O
mutations NNS O
, , O
associated VBN O
with IN O
increased VBN O
Wnt NNP O
signaling NN O
, , O
improve VB O
glucose NN O
metabolism NN O
in IN O
humans NNS O
. . O

However RB O
, , O
it PRP O
does VBZ O
appear VB O
that IN O
LRP5 NNP B-Gene
variants NNS B-Var
may MD O
affect VB B-Reg
LDL NNP B-MPA
metabolism NN I-MPA
The DT O
Microtubule-Associated NNP O
Protein NNP O
MAP18 NNP O
Affects NNPS O
ROP2 NNP O
GTPase NNP O
Activity NNP O
during IN O
Root NNP O
Hair NNP O
Growth NNP O
. . O

Establishment NNP O
and CC O
maintenance NN O
of IN O
the DT O
polar JJ O
site NN O
are VBP O
important JJ O
for IN O
root NN O
hair NN O
tip NN O
growth NN O
. . O

We PRP O
previously RB O
reported VBD O
that IN O
Arabidopsis NNP O
( -LRB- O
Arabidopsis NN O
thaliana NN O
) -RRB- O
MICROTUBULE-ASSOCIATED NNP O
PROTEIN18 NNP O
( -LRB- O
MAP18 NNP O
) -RRB- O
functions NNS O
in IN O
controlling VBG O
the DT O
direction NN O
of IN O
pollen NN O
tube NN O
growth NN O
and CC O
root NN O
hair NN O
elongation NN O
. . O

Additionally RB O
, , O
the DT O
Rop NNP O
GTPase NNP O
ROP2 NNP O
was VBD O
reported VBN O
as IN O
a DT O
positive JJ O
regulator NN O
of IN O
both DT O
root NN O
hair NN O
initiation NN O
and CC O
tip NN O
growth NN O
in IN O
Arabidopsis NNP O
. . O

Both DT O
loss NN B-NegReg
of IN I-NegReg
function NN I-NegReg
of IN O
ROP2 NNP B-Gene
and CC O
knockdown NN B-Var
of IN O
MAP18 NNP B-Gene
lead VB O
to IN O
a DT O
decrease NN B-NegReg
in IN O
root NN B-MPA
hair NN I-MPA
length NN I-MPA
A DT O
Ras NNP O
GTPase NNP O
associated VBN O
protein NN O
is VBZ O
involved VBN O
in IN O
the DT O
phototropic NN O
and CC O
circadian JJ O
photobiology NN O
responses NNS O
in IN O
fungi NNS O
. . O

Light NNP O
is VBZ O
an DT O
environmental JJ O
signal NN O
perceived VBN O
by IN O
most JJS O
eukaryotic JJ O
organisms NNS O
and CC O
that DT O
can MD O
have VB O
major JJ O
impacts NNS O
on IN O
their PRP$ O
growth NN O
and CC O
development NN O
. . O

The DT O
MadC NN O
protein NN O
in IN O
the DT O
fungus NN O
Phycomyces NNS O
blakesleeanus NN O
( -LRB- O
Mucoromycotina NNP O
) -RRB- O
has VBZ O
been VBN O
postulated VBN O
to TO O
form VB O
part NN O
of IN O
the DT O
photosensory JJ O
input NN O
for IN O
phototropism NN O
of IN O
the DT O
fruiting VBG O
body NN O
sporangiophores NNS O
, , O
but CC O
the DT O
madC NN O
gene NN O
has VBZ O
remained VBN O
unidentified JJ O
since IN O
the DT O
1960s NNS O
when WRB O
madC NN O
mutants NNS O
were VBD O
first RB O
isolated VBN O
. . O

In IN O
this DT O
study NN O
the DT O
madC NN O
gene NN O
was VBD O
identified VBN O
by IN O
positional JJ O
cloning VBG O
. . O

All DT O
madC NN O
mutant JJ O
strains NNS O
contain VBP O
loss-of-function NN O
point NN O
mutations NNS O
within IN O
a DT O
gene NN O
predicted VBD O
to TO O
encode VB O
a DT O
GTPase NN O
activating VBG O
protein NN O
( -LRB- O
GAP NNP O
) -RRB- O
for IN O
Ras NNP O
. . O

The DT O
madC NN O
gene NN O
complements VBZ O
the DT O
Saccharomyces NNPS O
cerevisiae VBP O
Ras-GAP NNP O
ira1 CC O
mutant JJ O
and CC O
the DT O
encoded VBN O
MadC NN O
protein NN O
interacts NNS O
with IN O
P. NNP O
blakesleeanus NN O
Ras NNP O
homologs NNS O
in IN O
yeast NN O
two-hybrid CD O
assays NNS O
, , O
indicating VBG O
that IN O
MadC NN O
is VBZ O
a DT O
regulator NN O
of IN O
Ras NNP O
signaling NN O
. . O

Deletion NN B-Var
of IN O
the DT O
homolog NN O
in IN O
the DT O
filamentous JJ O
ascomycete JJ O
Neurospora NNP O
crassa NN O
affects VBZ B-Reg
the DT O
circadian JJ B-MPA
clock NN I-MPA
output NN I-MPA
, , O
yielding VBG B-Reg
a DT O
pattern NN O
of IN O
asexual JJ B-MPA
conidiation NN I-MPA
Paradoxical JJ O
gain-of-function NN O
mutant NN O
of IN O
the DT O
G-protein-coupled NN O
receptor NN O
PROKR2 NNP O
promotes VBZ O
early JJ O
puberty NN O
. . O

The DT O
human JJ O
genome NN O
encodes NNS O
~750 . O
G-protein-coupled NN O
receptors NNS O
( -LRB- O
GPCRs FW O
) -RRB- O
, , O
including VBG O
prokineticin NNS O
receptor NN O
2 CD O
( -LRB- O
PROKR2 NN O
) -RRB- O
involved VBN O
in IN O
the DT O
regulation NN O
of IN O
sexual JJ O
maturation NN O
. . O

Previously RB O
reported VBD O
pathogenic JJ O
gain-of-function NN O
mutations NNS O
of IN O
GPCR NNP O
genes NNS O
invariably RB O
encoded VBD O
aberrant NN O
receptors NNS O
with IN O
excessive JJ O
signal NN O
transduction NN O
activity NN O
. . O

Although IN O
in IN O
vitro FW O
assays NNS O
demonstrated VBN O
that IN O
an DT O
artificially RB O
created VBN O
inactive NN O
mutant NN O
of IN O
PROKR2 NNS O
exerted VBD O
paradoxical JJ O
gain-of-function NN O
effects NNS O
when WRB O
co-transfected NN O
with IN O
wild-type JJ O
proteins NNS O
, , O
such PDT O
a DT O
phenomenon NN O
has VBZ O
not RB O
been VBN O
observed VBN O
in IN O
vivo NN O
. . O

Here RB O
, , O
we PRP O
report VBP O
a DT O
heterozygous JJ O
frameshift NN O
mutation NN O
of IN O
PROKR2 NNS O
identified VBN O
in IN O
a DT O
3.5-year-old CD O
girl NN O
with IN O
central JJ O
precocious JJ O
puberty NN O
. . O

The DT O
mutant JJ B-Var
mRNA NNS O
escaped VBD B-NegReg
nonsense-mediated NN B-MPA
decay NN I-MPA
and CC O
generated VBD O
a DT O
GPCR NNP O
lacking VBG B-NegReg
two CD B-MPA
transmembrane NN I-MPA
domains NNS I-MPA
and CC O
the DT O
carboxyl-terminal NN O
tail NN O
. . O

The DT O
mutant JJ O
protein NN O
had VBD O
no DT O
in IN O
vitro FW O
signal NN O
transduction NN O
activity NN O
; : O
however RB O
, , O
cells NNS O
co-expressing VBP O
the DT O
mutant JJ O
and CC O
wild-type JJ O
PROKR2 NNS O
exhibited VBD O
markedly RB O
exaggerated JJ O
ligand-induced NN O
Ca(2 NNP O
+ CC O
) -RRB- O
responses NNS O
. . O

The DT O
results NNS O
indicate VBP O
that IN O
certain JJ O
inactive JJ O
PROKR2 NNS B-Gene
mutants NNS B-Var
can MD O
cause VB O
early JJ O
puberty NN O
by IN O
enhancing VBG B-PosReg
the DT O
functional JJ B-MPA
property NN I-MPA
of IN I-MPA
coexisting VBG I-MPA
wild-type JJ I-MPA
proteins NNS I-MPA
The DT O
Tension-sensitive NN O
Ion NNP O
Transport NNP O
Activity NNP O
of IN O
MSL8 NNP O
is VBZ O
Critical JJ O
for IN O
its PRP$ O
Function NNP O
in IN O
Pollen NNP O
Hydration NNP O
and CC O
Germination NNP O
. . O

All DT O
cells NNS O
respond VBP O
to IN O
osmotic JJ O
challenges NNS O
, , O
including VBG O
those DT O
imposed VBN O
during IN O
normal JJ O
growth NN O
and CC O
development NN O
. . O

Mechanosensitive JJ O
( -LRB- O
MS NNP O
) -RRB- O
ion NN O
channels NNS O
provide VBP O
a DT O
conserved JJ O
mechanism NN O
for IN O
regulating VBG O
osmotic JJ O
forces NNS O
by IN O
conducting VBG O
ions NNS O
in IN O
response NN O
to IN O
increased VBN O
membrane JJ O
tension NN O
. . O

We PRP O
previously RB O
demonstrated VBD O
that IN O
the DT O
MS NNP O
ion NN O
channel NN O
MscS-Like NN O
8 CD O
( -LRB- O
MSL8 NNS O
) -RRB- O
is VBZ O
required VBN O
for IN O
pollen NN O
to TO O
survive VB O
multiple JJ O
osmotic JJ O
challenges NNS O
that WDT O
occur VBP O
during IN O
the DT O
normal JJ O
process NN O
of IN O
fertilization NN O
, , O
and CC O
that IN O
it PRP O
can MD O
inhibit VB O
pollen NN O
germination NN O
. . O

However RB O
, , O
it PRP O
remained VBD O
unclear JJ O
whether IN O
these DT O
physiological JJ O
functions NNS O
required VBD O
ion NN O
flux NN O
through IN O
a DT O
mechanically RB O
gated VBN O
channel NN O
provided VBN O
by IN O
MSL8 NNS O
. . O

We PRP O
introduced VBD O
two CD O
point NN O
mutations NNS B-Var
into IN O
the DT O
predicted VBN O
pore-lining NN O
domain NN O
of IN O
MSL8 NNPS B-Gene
that WDT O
disrupted VBD B-NegReg
normal JJ B-Pathway
channel NN I-Pathway
function NN I-Pathway
in IN O
different JJ O
ways NNS O
. . O

The DT O
Ile711Ser JJ B-Var
mutation NN I-Var
increased VBD B-PosReg
the DT O
tension NN B-MPA
threshold NN I-MPA
of IN O
the DT O
MSL8 NNPS B-Gene
channel NN O
while IN O
leaving VBG B-Reg
conductance NN B-MPA
unchanged JJ I-MPA
, , O
and CC O
the DT O
Phe720Leu NNP B-Var
mutation NN I-Var
severely RB O
disrupted VBD B-NegReg
the DT O
MSL8 NNPS B-Gene
channel NN B-Pathway
. . O

Both DT O
of IN O
these DT O
mutations NNS B-Var
impaired VBD B-NegReg
the DT O
ability NN B-MPA
of IN I-MPA
MSL8 NNPS I-MPA
to TO I-MPA
preserve VB I-MPA
pollen NN I-MPA
viability NN I-MPA
during IN I-MPA
hydration NN I-MPA
and CC O
to TO O
maintain VB B-Reg
the DT O
integrity NN B-MPA
of IN I-MPA
the DT I-MPA
pollen NN I-MPA
tube NN I-MPA
RACK1 NNS O
cooperates VBZ O
with IN O
NRAS(Q61 NNP O
K NNP O
) -RRB- O
to TO O
promote VB O
melanoma NN O
in IN O
vivo NN O
. . O

Melanoma NNP O
is VBZ O
the DT O
deadliest JJS O
skin NN O
cancer NN O
. . O

RACK1 NNS O
( -LRB- O
Receptor NN O
for IN O
activated VBN O
protein NN O
kinase NN O
C NNP O
) -RRB- O
protein NN O
was VBD O
proposed VBN O
as IN O
a DT O
biological JJ O
marker NN O
of IN O
melanoma NN O
in IN O
human JJ O
and CC O
domestic JJ O
animal NN O
species NNS O
harboring VBG O
spontaneous JJ O
melanomas NNS O
. . O

As IN O
a DT O
scaffold JJ O
protein NN O
, , O
RACK1 NNS O
is VBZ O
able JJ O
to TO O
coordinate VB O
the DT O
interaction NN O
of IN O
key JJ O
signaling NN O
molecules NNS O
implicated VBD O
in IN O
both DT O
physiological JJ O
cellular JJ O
functions NNS O
and CC O
tumorigenesis NN O
. . O

A DT O
role NN O
for IN O
RACK1 NNS O
in IN O
rewiring VBG O
ERK NNP O
and CC O
JNK NNP O
signaling NN O
pathways NNS O
in IN O
melanoma NN O
cell NN O
lines NNS O
had VBD O
been VBN O
proposed VBN O
. . O

Here RB O
, , O
we PRP O
used VBD O
a DT O
genetic JJ O
approach NN O
to TO O
test VB O
this DT O
hypothesis NN O
in IN O
vivo NN O
in IN O
the DT O
mouse NN O
. . O

We PRP O
show VBP O
that IN O
Rack1 NNP B-Gene
knock-down VB B-Var
in IN O
the DT O
mouse NN O
melanoma NN O
cell NN O
line NN O
B16 NNP O
reduces VBZ B-NegReg
invasiveness VBP B-MPA
and CC O
induces VBZ B-Reg
cell NN B-MPA
differentiation NN I-MPA
Identification NN O
and CC O
characterization NN O
of IN O
a DT O
novel JJ O
DGAT1 JJ O
missense NN O
mutation NN O
associated VBN O
with IN O
congenital JJ O
diarrhea NN O
. . O

Acyl-CoA NNP O
: : O
diacylglycerol NN O
acyltransferase NN O
( -LRB- O
DGAT)1 NN O
and CC O
DGAT2 VB O
catalyze NNS O
triglyceride NN O
( -LRB- O
TG NNP O
) -RRB- O
biosynthesis VBP O
in IN O
humans NNS O
. . O

Biallelic JJ O
loss-of-function NN B-NegReg
mutations NNS B-Var
in IN O
human JJ O
DGAT1 NNP B-Gene
result NN O
in IN O
severe JJ O
congenital JJ B-Disease
diarrhea NN I-Disease
and CC O
protein-losing NN B-Disease
enteropathy NN I-Disease
. . O

Additionally RB O
, , O
pharmacologic JJ O
inhibition NN O
of IN O
DGAT1 NNP O
led VBD O
to TO O
dose-related VB O
diarrhea NN O
in IN O
human JJ O
clinical JJ O
trials NNS O
. . O

Here RB O
we PRP O
identify VBP O
a DT O
previously RB O
unknown JJ O
DGAT1 JJ O
mutation NN O
in IN O
identical JJ O
twins NNS O
of IN O
South JJ O
Asian JJ O
descent NN O
. . O

These DT O
male JJ O
patients NNS O
developed VBD O
watery JJ O
diarrhea NN O
shortly RB O
after IN O
birth NN O
, , O
with IN O
protein-losing NN O
enteropathy NN O
and CC O
failure NN O
to TO O
thrive VB O
. . O

Exome JJ O
sequencing NN O
revealed VBD O
a DT O
homozygous JJ O
recessive JJ O
mutation NN O
in IN O
DGAT1 NNP O
, , O
c.314T FW O
> XX O
C NN O
, , O
p NN O
. . O

L105P. NN O
We PRP O
show VBP O
here RB O
that IN O
the DT O
p XX B-Var
. . O

L105P JJ O
DGAT1 NNP B-Gene
enzyme NN O
produced VBD O
from IN O
the DT O
mutant JJ B-Var
allele NN O
is VBZ O
less RBR B-NegReg
abundant JJ O
, , O
resulting VBG O
in IN O
partial JJ O
loss NN B-NegReg
of IN O
TG NNP B-MPA
synthesis NN I-MPA
activity NN I-MPA
and CC O
decreased VBD B-NegReg
formation NN B-MPA
of IN I-MPA
lipid NN I-MPA
droplets NNS I-MPA
in IN O
patient-derived NN O
primary JJ O
dermal JJ O
fibroblasts NNS O
. . O

Thus RB O
, , O
in IN O
contrast NN O
with IN O
complete JJ O
loss-of-function NN O
alleles NNS O
of IN O
DGAT1 NNP O
, , O
the DT O
p NN B-Var
. . I-Var
L105P JJ O
missense NN O
allele NN O
partially RB O
reduces VBZ B-NegReg
TG NNP B-MPA
synthesis NN I-MPA
activity NN I-MPA
and CC O
causes VBZ B-Reg
a DT O
less RBR B-MPA
severe JJ I-MPA
clinical JJ I-MPA
phenotype NN I-MPA
. . O

Our PRP$ O
findings NNS O
add VBP O
to IN O
the DT O
growing VBG O
recognition NN O
of IN O
DGAT1 JJ B-Gene
deficiency NN B-Var
as IN O
a DT O
cause NN B-Reg
of IN O
congenital JJ B-Disease
diarrhea NN I-Disease
with IN O
protein-losing NN B-Disease
enteropathy JJ I-Disease
and CC O
indicate VBP O
that IN O
DGAT1 JJ B-Gene
mutations NNS B-Var
result VBP B-Reg
in IN I-Reg
a DT O
spectrum NN B-Disease
of IN I-Disease
diseases NNS I-Disease
Hydrocephalus IN B-Disease
due JJ O
to IN O
multiple JJ O
ependymal JJ O
malformations NNS O
is VBZ O
caused VBN B-Reg
by IN I-Reg
mutations NNS B-Var
in IN O
the DT O
MPDZ NNP B-Gene
gene NN O
. . O

Congenital JJ O
hydrocephalus NN O
is VBZ O
considered VBN O
as IN O
either CC O
acquired VBN O
due JJ O
to IN O
haemorrhage NN O
, , O
infection NN O
or CC O
neoplasia NN O
or CC O
as IN O
of IN O
developmental JJ O
nature NN O
and CC O
is VBZ O
divided VBN O
into IN O
two CD O
subgroups NNS O
, , O
communicating VBG O
and CC O
obstructive JJ O
. . O

Congenital JJ O
hydrocephalus NN O
is VBZ O
either CC O
syndromic JJ O
or CC O
non-syndromic AFX O
, , O
and CC O
in IN O
the DT O
latter JJ O
no DT O
cause NN O
is VBZ O
found VBN O
in IN O
more JJR O
than IN O
half NN O
of IN O
the DT O
patients NNS O
. . O

In IN O
patients NNS O
with IN O
isolated JJ B-Disease
hydrocephalus NN I-Disease
, , O
L1CAM NNP B-Gene
mutations NNS B-Var
represent VBP O
the DT O
most RBS O
common JJ B-Reg
Short JJ O
hairpin NN O
RNA NNP O
is VBZ O
more RBR O
effective JJ O
than IN O
long JJ O
hairpin NN O
RNA NN O
in IN O
eliciting VBG O
pointed JJ O
loss-of-function NN O
phenotypes NNS O
in IN O
Drosophila NNP O
. . O

Pointed NNP O
( -LRB- O
Pnt NNP O
) -RRB- O
is VBZ O
a DT O
transcriptional JJ O
activator NN O
that WDT O
functions VBZ O
downstream RB O
of IN O
the DT O
highly RB O
conserved VBN O
Receptor NNP O
Tyrosine NNP O
Kinase NNP O
( -LRB- O
RTK NNP O
) -RRB- O
signaling NN O
pathway NN O
. . O

Pnt NNP O
is VBZ O
an DT O
ETS NNP O
family NN O
transcription NN O
factor NN O
and CC O
encodes NNS O
for IN O
two CD O
proteins NNS O
, , O
PntP1 NNP O
and CC O
PntP2 NNP O
. . O

However RB O
, , O
while IN O
PntP1 NNP O
is VBZ O
constitutively RB O
active JJ O
, , O
PntP2 NNP O
is VBZ O
only RB O
active JJ O
after IN O
being VBG O
phosphorylated VBN O
by IN O
MAPK NN O
in IN O
the DT O
RTK NNP O
pathway NN O
. . O

As IN O
mutations NNS B-Var
in IN O
pnt NN B-Gene
perturb NN B-Reg
the DT O
development NN B-CPA
of IN I-CPA
several JJ I-CPA
tissues NNS I-CPA
New JJ O
gain-of-function NN B-PosReg
mutation NN B-Var
shows VBZ O
CACNA1D NNP B-Gene
as IN O
recurrently RB O
mutated VBD O
gene NN O
in IN O
autism NN B-Disease
spectrum NN I-Disease
disorders NNS I-Disease
and CC O
epilepsy NN B-Disease
. . O

CACNA1D NNP O
encodes VBZ O
the DT O
pore-forming NN O
of IN O
Cav1.3 NN O
, , O
an DT O
L-type NN O
voltage-gated NN O
Ca2 NN O
+ SYM O
-channel CD O
. . O

Despite IN O
the DT O
recent JJ O
discovery NN O
of IN O
two CD O
de FW O
novo NN O
missense NN O
gain-of-function NN O
mutations NNS O
in IN O
Cav1.3 NN O
in IN O
two CD O
individuals NNS O
with IN O
autism NN O
spectrum NN O
disorder NN O
( -LRB- O
ASD NN O
) -RRB- O
and CC O
intellectual JJ O
disability NN O
CACNA1D NN O
has VBZ O
not RB O
been VBN O
considered VBN O
a DT O
prominent JJ O
ASD-risk NNP O
gene NN O
in IN O
large JJ O
scale NN O
genetic JJ O
analyses NNS O
, , O
since IN O
such JJ O
studies NNS O
primarly RB O
focus VBP O
on IN O
likely-disruptive JJ O
genetic JJ O
variants NNS O
. . O

Here RB O
we PRP O
report VBP O
the DT O
discovery NN O
and CC O
characterization NN O
of IN O
a DT O
third JJ O
de FW O
novo NN O
missense NN O
mutation NN O
in IN O
CACNA1D NNP O
( -LRB- O
V401L NNP O
) -RRB- O
in IN O
a DT O
patient NN O
with IN O
ASD NN O
and CC O
epilepsy NN O
. . O

For IN O
the DT O
functional JJ O
characterization NN O
we PRP O
introduced VBD O
mutation NN O
V401L NNP O
into IN O
two CD O
major JJ O
C-terminal NN O
long RB O
and CC O
short JJ O
Cav1.3 JJ O
splice NN O
variants NNS O
, , O
expressed VBD O
wild-type JJ O
or CC O
mutant JJ O
channel NN O
complexes NNS O
in IN O
tsA-201 NN O
cells NNS O
and CC O
performed VBD O
whole-cell JJ O
patch-clamp NN O
recordings NNS O
. . O

Mutation NNP O
V401L NNP B-Var
, , O
localized VBN O
within IN O
the DT O
channel NN O
's POS O
activation NN O
gate NN O
, , O
significantly RB O
enhanced VBN B-PosReg
current JJ B-MPA
densities NNS I-MPA
, , O
shifted VBD O
voltage NN O
dependence NN O
of IN O
activation NN O
and CC O
inactivation NN O
to IN O
more RBR O
negative JJ O
voltages NNS O
and CC O
reduced VBN O
channel NN O
inactivation NN O
in IN O
both DT O
Cav1.3 JJ O
splice NN O
variants NNS O
. . O

Altogether RB O
these DT O
gating NN O
changes NNS B-Var
are VBP O
expected VBN O
to TO O
result VB O
in IN O
enhanced JJ B-PosReg
Ca2 NN B-MPA
+ SYM I-MPA
-influx : I-MPA
through IN I-MPA
Proteomic JJ O
analysis NN O
of IN O
filaggrin NN O
deficiency NN O
identifies VBZ O
molecular JJ O
signatures NNS O
characteristic JJ O
of IN O
atopic JJ O
eczema NN O
. . O

BACKGROUND NNP O
: : O
Atopic NNP B-Disease
eczema NN I-Disease
( -LRB- O
AE NNP O
) -RRB- O
is VBZ O
characterized VBN O
by IN O
skin NN O
barrier NN O
and CC O
immune JJ O
dysfunction NN O
. . O

Null NN B-Var
mutations NNS I-Var
in IN O
filaggrin NN O
( -LRB- O
FLG NNP B-Gene
) -RRB- O
, , O
a DT O
key JJ O
epidermal JJ O
barrier NN O
protein NN O
, , O
strongly RB O
predispose VBD B-Reg
to IN O
AE NN B-Disease
; : O
however RB O
, , O
the DT O
precise JJ O
role NN O
of IN O
FLG NNP O
deficiency NN O
in IN O
AE NN O
pathogenesis NN O
remains VBZ O
incompletely RB O
understood VBN O
. . O

OBJECTIVES NNS O
: : O
We PRP O
sought VBD O
to TO O
identify VB O
global JJ O
proteomic JJ O
changes NNS O
downstream RB O
of IN O
FLG NNP O
deficiency NN O
in IN O
human JJ O
epidermal JJ O
living VBG O
skin-equivalent NN O
( -LRB- O
LSE NNP O
) -RRB- O
models NNS O
and CC O
validate JJ O
findings NNS O
in IN O
skin NN O
of IN O
patients NNS O
with IN O
AE NNP O
. . O

METHODS NNS O
: : O
Differentially NNP O
expressed VBD O
proteins NNS O
from IN O
paired VBN O
control NN O
( -LRB- O
nontargeting VBG O
control NN O
short JJ O
hairpin NN O
RNA NNP O
[ -LRB- O
shNT NNP O
] -RRB- O
) -RRB- O
and CC O
FLG NNP O
knockdown NN O
( -LRB- O
FLG NNP O
knockdown VBD O
short JJ O
hairpin NN O
RNA NNP O
[ -LRB- O
shFLG NNP O
] -RRB- O
) -RRB- O
LSEs NNS O
were VBD O
identified VBN O
by IN O
means NNS O
of IN O
proteomic JJ O
analysis NN O
( -LRB- O
liquid JJ O
chromatography-mass NN O
spectrometry NN O
) -RRB- O
and CC O
Ingenuity NNP O
Pathway NNP O
Analysis NNP O
. . O

Expression NN O
of IN O
key JJ O
targets NNS O
was VBD O
validated VBN O
in IN O
independent JJ O
LSE NNP O
samples NNS O
( -LRB- O
quantitative JJ O
RT-PCR NNP O
and CC O
Western JJ O
blotting NN O
) -RRB- O
and CC O
in IN O
normal JJ O
and CC O
AE NN O
skin NN O
biopsy NN O
specimens NNS O
( -LRB- O
immunofluorescence NN O
) -RRB- O
. . O

RESULTS NNP O
: : O
Proteomic JJ O
analysis NN O
identified VBD O
17 CD O
( -LRB- O
P NN O
.05 CD O
) -RRB- O
differentially RB O
expressed VBD O
proteins NNS O
after IN O
FLG NNP O
knockdown NN O
, , O
including VBG O
kallikrein-7 NNP O
( -LRB- O
KLK7 NNP O
; : O
2.2-fold CD O
) -RRB- O
, , O
cyclophilin VB O
A DT O
( -LRB- O
PPIA NN O
; : O
0.9-fold JJ O
) -RRB- O
, , O
and CC O
cofilin-1 NNP O
( -LRB- O
CFL1 NNP O
, , O
1.3-fold CD O
) -RRB- O
. . O

Differential JJ O
protein NN O
expression NN O
was VBD O
confirmed VBN O
in IN O
shNT NNP O
/ SYM O
shFLG NNP O
LSEs NNS O
; : O
however RB O
, , O
only RB O
KLK7 NNP O
was VBD O
transcriptionally RB O
dysregulated VBN O
. . O

Molecular JJ B-Pathway
pathways NNS I-Pathway
overrepresented VBN B-PosReg
after IN O
FLG NNP B-Gene
knockdown NN B-Var
included VBD O
inflammation NN O
, , O
protease JJ O
activity NN O
, , O
cell NN O
structure NN O
, , O
and CC O
stress NN O
. . O

Furthermore RB O
, , O
KLK7 NNP O
( -LRB- O
1.8-fold CD O
) -RRB- O
and CC O
PPIA NNP O
( -LRB- O
0.65-fold NNP O
) -RRB- O
proteins NNS O
were VBD O
differentially RB O
expressed VBN O
in IN O
lesional JJ O
biopsy NN O
specimens NNS O
from IN O
patients NNS O
with IN O
AE NNP O
relative NN O
to IN O
normal JJ O
skin NN O
. . O

CONCLUSIONS NNS O
: : O
For IN O
the DT O
first JJ O
time NN O
, , O
we PRP O
show VBP O
that IN O
loss NN B-Var
of IN O
FLG NNP B-Gene
in IN O
the DT O
absence NN O
of IN O
inflammation NN O
is VBZ O
sufficient JJ O
to TO O
alter VB B-Reg
the DT O
expression NN B-MPA
level NN I-MPA
of IN I-MPA
proteins NNS I-MPA
TREM2 RB O
deficiency NN O
impairs NNS O
chemotaxis CD O
and CC O
microglial JJ O
responses NNS O
to IN O
neuronal JJ O
injury NN O
. . O

Sequence NNP O
variations NNS B-Var
in IN O
the DT O
triggering VBG O
receptor NN O
expressed VBN O
on IN O
myeloid NN O
cells NNS O
2 CD O
( -LRB- O
TREM2 RB B-Gene
) -RRB- O
have VBP O
been VBN O
linked VBN B-Reg
to IN I-Reg
an DT O
increased VBN O
risk NN O
for IN O
neurodegenerative JJ O
disorders NNS O
such JJ O
as IN O
Alzheimer NNP B-Disease
's POS I-Disease
disease NN O
and CC O
frontotemporal JJ B-Disease
lobar NN I-Disease
degeneration NN I-Disease
. . O

In IN O
the DT O
brain NN O
, , O
TREM2 RB O
is VBZ O
predominantly RB O
expressed VBN O
in IN O
microglia NNS O
. . O

Several JJ O
disease-associated NN O
TREM2 RB B-Gene
variants NNS B-Var
result VBP O
in IN O
a DT O
loss NN O
of IN O
function NN O
by IN O
reducing VBG B-NegReg
microglial JJ B-CPA
phagocytosis NN I-CPA
, , O
impairing VBG B-NegReg
lipid NN B-MPA
sensing NN I-MPA
, , O
preventing VBG B-NegReg
binding VBG B-Interaction
of IN O
lipoproteins NNS B-Protein
and CC O
affecting VBG B-Reg
shielding NN B-MPA
of IN I-MPA
amyloid NN I-MPA
plaques NNS I-MPA
. . O

We PRP O
here RB O
investigate VBP O
the DT O
consequences NNS O
of IN O
TREM2 RB O
loss NN O
of IN O
function NN O
on IN O
the DT O
microglia NNS O
transcriptome VBP O
. . O

Among IN O
the DT O
differentially RB O
expressed VBN O
messenger NN O
RNAs NNS O
in IN O
wild-type JJ O
and CC O
Trem2(-/- VB O
) -RRB- O
microglia NN O
, , O
gene NN O
clusters NNS O
are VBP O
identified VBN O
which WDT O
represent VBP O
gene NN O
functions NNS O
in IN O
chemotaxis NNS O
, , O
migration NN O
and CC O
mobility NN O
. . O

Functional JJ O
analyses NNS O
confirm VBP O
that IN O
loss NN B-Var
of IN O
TREM2 RB B-Gene
impairs NNS B-NegReg
appropriate JJ O
microglial JJ B-CPA
responses NNS I-CPA
to IN I-CPA
injury NN I-CPA
and CC I-CPA
signals NNS I-CPA
Novel JJ O
loss NN B-NegReg
of IN I-NegReg
function NN I-NegReg
mutation NN B-Var
in IN O
KRIT1/CCM1 NNP B-Gene
is VBZ O
associated VBN B-Reg
with IN I-Reg
distinctly RB O
progressive JJ O
cerebral JJ B-Disease
and CC I-Disease
spinal JJ I-Disease
cavernous JJ I-Disease
malformations NNS I-Disease
after IN O
radiochemotherapy NN O
for IN O
intracranial JJ O
malignant JJ O
germ JJ O
cell NN O
tumor NN O
. . O

PURPOSE NNP O
: : O
Cerebrospinal JJ B-Disease
cavernous JJ I-Disease
malformations NNS I-Disease
( -LRB- O
CCMs NNS O
) -RRB- O
are VBP O
vascular JJ O
lesions NNS O
characterized VBN O
by IN O
dilated JJ O
and CC O
leaky JJ O
capillary JJ O
caverns NNS O
. . O

CCMs NNS O
can MD O
cause VB O
seizures NNS O
, , O
focal JJ O
neurological JJ O
deficits NNS O
or CC O
acute JJ O
intracranial JJ O
hemorrhage NN O
; : O
however RB O
, , O
most JJS O
patients NNS O
are VBP O
asymptomatic JJ O
. . O

CCMs NNS O
occur VBP O
either CC O
sporadically RB O
or CC O
as IN O
a DT O
familial JJ O
autosomal-dominant NN O
disorder NN O
. . O

We PRP O
present VBP O
a DT O
clinical JJ O
and CC O
molecular JJ O
study NN O
of IN O
a DT O
patient NN O
with IN O
distinctive JJ O
cerebral JJ O
and CC O
spinal JJ O
cavernous JJ O
malformations NNS O
following VBG O
radiochemotherapy NN O
for IN O
a DT O
malignant JJ O
brain NN O
tumor NN O
. . O

METHODS NNS O
: : O
The DT O
patient NN O
had VBD O
multiple JJ O
magnet NN O
resonance NN O
imaging NN O
( -LRB- O
MRI NNP O
) -RRB- O
examinations NNS O
of IN O
his PRP$ O
brain NN O
and CC O
spine NN O
following VBG O
radiochemotherapy NN O
for IN O
a DT O
primary JJ O
intracranial JJ O
germ NN O
cell NN O
tumor NN O
( -LRB- O
GCT NNP O
) -RRB- O
, , O
as IN O
part NN O
of IN O
his PRP$ O
oncologic JJ O
follow-up NN O
. . O

The DT O
MRI NNP O
sequences NNS O
included VBD O
susceptibility-weighted NN O
imaging NN O
( -LRB- O
SWI NNP O
) -RRB- O
. . O

The DT O
coding VBG O
exons NNS O
and CC O
their PRP$ O
flanking VBG O
intronic JJ O
regions NNS O
of IN O
KRIT1/CCM1 JJ O
gene NN O
were VBD O
analyzed VBN O
for IN O
mutations NNS O
by IN O
polymerase NN O
chain NN O
reaction NN O
( -LRB- O
PCR NNP O
) -RRB- O
and CC O
direct JJ O
sequencing NN O
. . O

RESULTS NNP O
: : O
MRI NNP O
revealed VBD O
numerous JJ O
cerebral JJ O
and CC O
spinal JJ O
microhemorrhages NNS O
and CC O
pronounced VBN O
cavernous JJ O
malformations NNS O
that WDT O
progressed VBD O
with IN O
subsequent JJ O
follow-up NN O
imaging NN O
. . O

Genetic JJ O
analysis NN O
demonstrated VBD O
a DT O
novel JJ O
heterozygous JJ O
KRIT1/CCM1 NNP B-Gene
two CD O
base NN O
pair NN O
deletion NN O
( -LRB- O
c.1535_1536delTG JJ B-Var
) -RRB- O
in IN O
exon NN O
14 CD O
. . O

This DT O
deletion NN O
leads VBZ B-Reg
to IN I-Reg
a DT O
frameshift NN B-Var
with IN O
a DT O
premature JJ B-MPA
stop NN I-MPA
codon VBN I-MPA
at IN O
nucleotide NN O
position NN O
1553 CD O
and CC O
a DT O
highly RB O
likely JJ O
loss NN B-NegReg
of IN I-NegReg
function NN I-NegReg
of IN O
the DT O
KRIT1 NNP B-Protein
protein NN I-Protein
. . O

CONCLUSION NN O
: : O
We PRP O
describe VBP O
a DT O
patient NN O
with IN O
a DT O
novel JJ O
heterozygous JJ O
germ JJ O
line NN O
loss NN B-NegReg
of IN I-NegReg
function NN I-NegReg
mutation NN B-Var
in IN O
KRIT1 NNP B-Gene
, , O
which WDT O
is VBZ O
associated VBN B-Reg
with IN I-Reg
rapid-onset JJ O
and CC O
highly RB O
progressive JJ O
CCMs NNS B-Disease
Real-World JJ O
Data NNP O
on IN O
Prognostic NNP O
Factors NNPS O
for IN O
Overall NNP O
Survival NNP O
in IN O
EGFR NNP B-Gene
Mutation-Positive NNP B-Var
Advanced NNP O
Non-Small NNP O
Cell NNP O
Lung NNP O
Cancer NNP O
Patients NNPS O
Treated VBN O
with IN O
First-Line JJ O
Gefitinib NNP O
. . O

BACKGROUND NNP O
: : O
This DT O
study NN O
aimed VBD O
to TO O
identify VB O
independent JJ O
prognostic JJ O
factors NNS O
for IN O
overall JJ O
survival NN O
( -LRB- O
OS NNP O
) -RRB- O
of IN O
patients NNS O
with IN O
advanced JJ O
non-small AFX O
cell NN O
lung NN O
cancer NN O
( -LRB- O
NSCLC NNP O
) -RRB- O
harboring VBG O
an DT O
activating VBG O
epidermal JJ O
growth NN O
factor NN O
receptor NN O
( -LRB- O
EGFR NNP O
) -RRB- O
mutation NN O
and CC O
receiving VBG O
gefitinib NN O
as IN O
first-line JJ O
treatment NN O
in IN O
real-world JJ O
practice NN O
. . O

MATERIALS NNS O
AND CC O
METHODS NNS O
: : O
We PRP O
enrolled VBD O
226 CD O
patients NNS O
from IN O
June NNP O
2011 CD O
to IN O
May NNP O
2013 CD O
. . O

During IN O
this DT O
period NN O
, , O
gefitinib NN O
was VBD O
the DT O
only JJ O
EGFR-tyrosine NNP O
kinase NN O
inhibitor NN O
reimbursed VBN O
by IN O
the DT O
Bureau NNP O
of IN O
National NNP O
Health NNP O
Insurance NNP O
of IN O
Taiwan NNP O
. . O

RESULTS NNS O
: : O
The DT O
median JJ O
progression-free NN O
survival NN O
and CC O
median JJ O
OS NNP O
were VBD O
11.9 CD O
months NNS O
( -LRB- O
95 CD O
% NN O
confidence NN O
interval NN O
[ -LRB- O
CI NNP O
] -RRB- O
: : O
9.7-14.2 CD O
) -RRB- O
and CC O
26.9 CD O
months NNS O
( -LRB- O
21.2-32.5 CD O
) -RRB- O
, , O
respectively RB O
. . O

The DT O
Cox NNP O
proportional JJ O
hazards NNS O
regression NN O
model NN O
revealed VBD O
that IN O
postoperative JJ O
recurrence NN O
, , O
performance NN O
status NN O
( -LRB- O
Eastern JJ O
Cooperative NNP O
Oncology NN O
Grade NNP O
[ -LRB- O
ECOG NNP O
] -RRB- O
) -RRB- O
, , O
smoking NN O
index NN O
( -LRB- O
pack-years NN O
) -RRB- O
, , O
liver NN O
metastasis NN O
at IN O
initial JJ O
diagnosis NN O
, , O
and CC O
chronic JJ O
hepatitis NNP O
C NNP O
virus NN O
( -LRB- O
HCV NNP O
) -RRB- O
infection NN O
were VBD O
independent JJ O
prognostic JJ O
factors NNS O
for IN O
OS NNP O
( -LRB- O
hazard NN O
ratio NN O
[ -LRB- O
95 CD O
% NN O
CI NNP O
] -RRB- O
0.3 CD O
[ -LRB- O
0.11-0.83 CD O
] -RRB- O
, , O
p DT O
= SYM O
.02 CD O
; : O
2.69 CD O
[ -LRB- O
1.60-4.51 CD O
] -RRB- O
, , O
p DT O
< XX O
.001 CD O
; : O
1.92 CD O
[ -LRB- O
1.24-2.97 CD O
] -RRB- O
, , O
p DT O
= SYM O
.003 CD O
; : O
2.26 CD O
[ -LRB- O
1.34-3.82 CD O
] -RRB- O
, , O
p DT O
= SYM O
.002 CD O
; : O
3.38 CD O
[ -LRB- O
1.85-7.78 CD O
] -RRB- O
, , O
p DT O
< XX O
.001 CD O
, , O
respectively RB O
) -RRB- O
. . O

However RB O
, , O
brain NN O
metastasis NN O
( -LRB- O
BM NNP O
) -RRB- O
at IN O
initial JJ O
diagnosis NN O
or CC O
intracranial JJ O
progression NN O
during IN O
gefitinib NN O
treatment NN O
had VBD O
no DT O
impact NN O
on IN O
OS NNP O
( -LRB- O
1.266 CD O
[ -LRB- O
0.83-1.93 CD O
] -RRB- O
, , O
p DT O
= SYM O
.275 CD O
and CC O
0.75 CD O
[ -LRB- O
0.48-1.19 CD O
] -RRB- O
, , O
p DT O
= SYM O
.211 CD O
, , O
respectively RB O
) -RRB- O
. . O

CONCLUSION NN O
: : O
HCV NNP O
infection NN O
, , O
performance NN O
status NN O
( -LRB- O
ECOG NNP O
) -RRB- O
, , O
newly RB O
diagnosed VBN O
advanced JJ O
NSCLC NNP O
without IN O
prior JJ O
operation NN O
, , O
and CC O
liver NN O
metastasis NN O
predicted VBD O
poor JJ O
OS NN O
in IN O
EGFR NNP O
mutation-positive NN O
advanced JJ O
NSCLC NNP O
patients NNS O
treated VBN O
with IN O
first-line JJ O
gefitinib NN O
; : O
however RB O
, , O
neither CC O
BM NNP O
at IN O
initial JJ O
diagnosis NN O
nor CC O
intracranial JJ O
progression NN O
during IN O
gefitinib NN O
treatment NN O
had VBD O
an DT O
impact NN O
on IN O
OS NNP O
. . O

The DT O
Oncologist NNP O
2017;22:1-9 CD O
IMPLICATIONS NNS O
FOR IN O
PRACTICE NN O
: : O
The DT O
finding NN O
that IN O
chronic JJ O
hepatitis NNP O
C NNP O
virus NN O
( -LRB- O
HCV NNP O
) -RRB- O
infection NN O
might MD O
predict VB O
poor JJ O
overall JJ O
survival NN O
( -LRB- O
OS NNP O
) -RRB- O
in IN O
epidermal JJ O
growth NN O
factor NN O
receptor NN O
mutation-positive NN O
advanced JJ O
non-small AFX O
cell NN O
lung NN O
cancer NN O
( -LRB- O
NSCLC NNP O
) -RRB- O
patients NNS O
treated VBN O
with IN O
first-line JJ O
gefitinib NN O
may MD O
raise VB O
awareness NN O
of IN O
benefit NN O
from IN O
anti-HCV RB O
treatment NN O
in IN O
this DT O
patient JJ O
population NN O
. . O

Brain NN O
metastasis NN O
in IN O
the DT O
initial JJ O
diagnosis NN O
or CC O
intracranial JJ O
progression NN O
during IN O
gefitinib NN O
treatment NN O
is VBZ O
not RB O
a DT O
prognostic JJ O
factor NN O
for IN O
OS NNP O
. . O

This DT O
study NN O
, , O
which WDT O
enrolled VBD O
a DT O
real-world JJ O
population NN O
of IN O
NSCLC NNP O
patients NNS O
, , O
including VBG O
sicker NN O
patients NNS O
who WP O
were VBD O
not RB O
eligible JJ O
for IN O
a DT O
clinical JJ O
trial NN O
, , O
may MD O
have VB O
impact NN O
on IN O
guiding VBG O
usual JJ O
clinical JJ O
practice NN O
. . O

Loss NN B-Var
of IN O
the DT O
homologous JJ O
recombination NN O
gene NN O
rad51 NNP B-Gene
leads VBZ B-Reg
to IN O
Fanconi NNP B-Disease
anemia-like NN I-Disease
symptoms NNS I-Disease
in IN O
zebrafish NN O
. . O

RAD51 NNP O
is VBZ O
an DT O
indispensable JJ O
homologous JJ O
recombination NN O
protein NN O
, , O
necessary JJ O
for IN O
strand JJ O
invasion NN O
and CC O
crossing VBG O
over RB O
. . O

It PRP O
has VBZ O
recently RB O
been VBN O
designated VBN O
as IN O
a DT O
Fanconi NNP B-Disease
anemia NN I-Disease
( -LRB- O
FA NNP O
) -RRB- O
gene NN O
, , O
following VBG O
the DT O
discovery NN O
of IN O
two CD O
patients NNS O
carrying VBG O
dominant-negative JJ O
mutations NNS O
. . O

FA NNP O
is VBZ O
a DT O
hereditary JJ O
DNA-repair NN O
disorder NN O
characterized VBN O
by IN O
various JJ O
congenital JJ O
abnormalities NNS O
, , O
progressive JJ O
bone NN O
marrow NN O
failure NN O
, , O
and CC O
cancer NN O
predisposition NN O
. . O

In IN O
this DT O
report NN O
, , O
we PRP O
describe VBP O
a DT O
viable JJ O
vertebrate NN O
model NN O
of IN O
RAD51 NNP O
loss NN O
. . O

Zebrafish NNP O
rad51 NNP B-Gene
loss-of-function NN B-NegReg
mutants NNS B-Var
developed VBD O
key JJ O
features NNS O
of IN O
FA NNP B-Disease
Gene NNP O
Co-Expression NNP O
Network NNP O
Analysis NNP O
for IN O
Identifying VBG O
Modules NNPS O
and CC O
Functionally RB O
Enriched NNP O
Pathways NNPS O
in IN O
SCA2 NNP O
. . O

Spinocerebellar NNP B-Disease
ataxia NN I-Disease
type NN I-Disease
2 CD I-Disease
( -LRB- O
SCA2 NNP O
) -RRB- O
is VBZ O
an DT O
autosomal JJ O
dominant JJ O
neurodegenerative JJ O
disease NN O
caused VBN B-Reg
by IN I-Reg
CAG NNP B-Var
repeat NN I-Var
expansion NN I-Var
in IN O
the DT O
ATXN2 NNP B-Gene
Exposure NN O
to IN O
phenols NNS O
, , O
parabens NNS O
and CC O
UV NN O
filters NNS O
: : O
Associations NNS O
with IN O
loss-of-function NN O
mutations NNS O
in IN O
the DT O
filaggrin NN O
gene NN O
in IN O
men NNS O
from IN O
the DT O
general JJ O
population NN O
. . O

BACKGROUND NNP O
: : O
Filaggrin NNP O
is VBZ O
an DT O
epidermal JJ O
protein NN O
that WDT O
is VBZ O
important JJ O
for IN O
normal JJ O
skin NN O
barrier NN O
functions NNS O
. . O

Up IN O
to TO O
10 CD O
% NN O
of IN O
Europeans NNPS O
and CC O
Asians NNPS O
carry VBP O
filaggrin NN O
gene NN O
( -LRB- O
FLG NNP B-Gene
) -RRB- O
loss-of NN B-NegReg
function NN I-NegReg
mutations NNS B-Var
that WDT O
appear VBP O
to TO O
facilitate VB B-PosReg
trans-epidermal NNS B-CPA
penetration NN I-CPA
of IN I-CPA
certain JJ I-CPA
chemicals NNS I-CPA
GRIN2B VB O
gain NN O
of IN O
function NN O
mutations NNS O
are VBP O
sensitive JJ O
to IN O
radiprodil VB O
, , O
a DT O
negative JJ O
allosteric JJ O
modulator NN O
of IN O
GluN2B-containing NNP O
NMDA NNP O
receptors NNS O
. . O

De NNP O
novo NN O
gain NN B-PosReg
of IN I-PosReg
function NN I-PosReg
mutations NNS B-Var
in IN O
GRIN2B NNP B-Gene
encoding VBG O
the DT O
GluN2B NN O
subunit NN O
of IN O
the DT O
N-methyl-d-aspartate NNP O
( -LRB- O
NMDA NNP O
) -RRB- O
receptor NN O
have VBP O
been VBN O
linked VBN O
with IN O
epileptic JJ B-Disease
encephalopathies NNS I-Disease
, , O
including VBG O
infantile JJ B-Disease
spasms NNS I-Disease
PAI-1 VB O
gain-of-function VB O
genotype NN O
, , O
factors NNS O
increasing VBG O
PAI-1 NN O
levels NNS O
, , O
and CC O
airway NN O
obstruction NN O
: : O
The DT O
GALA NNP O
II NNP O
Cohort NNP O
. . O

BACKGROUND NNP O
: : O
PAI-1 VB B-Gene
gain-of-function VB O
variants NNS B-Var
promote VBP B-PosReg
airway NN B-CPA
fibrosis NN I-CPA
and CC O
are VBP O
associated VBN B-Reg
with IN I-Reg
asthma NN B-Disease
Severe JJ O
hypertriglyceridemia NN B-Disease
due JJ O
to IN O
two CD O
novel JJ O
loss-of-function NN B-NegReg
lipoprotein NN B-Enzyme
lipase NN I-Enzyme
gene NN O
mutations NNS O
( -LRB- O
C310R NNP B-Var
/ SYM O
E396V NN B-Var
) -RRB- O
in IN O
a DT O
Chinese JJ O
family NN O
associated VBN B-Reg
with IN I-Reg
recurrent JJ B-Disease
acute JJ I-Disease
pancreatitis NN I-Disease
. . O

Lipoprotein NNP O
lipase NN O
( -LRB- O
LPL NNP O
) -RRB- O
is VBZ O
widely RB O
expressed VBN O
in IN O
skeletal JJ O
muscles NNS O
, , O
cardiac JJ O
muscles NNS O
as RB O
well RB O
as IN O
adipose PRP$ O
tissue NN O
and CC O
involved VBN O
in IN O
the DT O
catabolism NN O
of IN O
triglyceride NN O
. . O

Herein NNP O
we PRP O
have VBP O
systematically RB O
characterized VBN O
two CD O
novel JJ O
loss-of-function NN O
mutations NNS O
in IN O
LPL NNP O
from IN O
a DT O
Chinese JJ O
family NN O
in IN O
which WDT O
afflicted VBN O
members NNS O
were VBD O
manifested VBN O
by IN O
severe JJ O
hypertriglyceridemia NN O
and CC O
recurrent JJ O
pancreatitis NN O
. . O

DNA NN O
sequencing NN O
revealed VBD O
that IN O
the DT O
proband NN O
was VBD O
a DT O
heterozygote NN O
carrying VBG O
a DT O
novel NN O
c NN O
. . O

T928C NN O
( -LRB- O
p NN O
. . O

C310R NN O
) -RRB- O
mutation NN O
in IN O
exon NN O
6 CD O
of IN O
the DT O
LPL NNP O
gene NN O
. . O

Another DT O
member NN O
of IN O
the DT O
family NN O
was VBD O
detected VBN O
to TO O
be VB O
a DT O
compound JJ O
heterozygote NN O
who WP O
along IN O
with IN O
the DT O
c NN O
. . O

T928C NN O
mutation NN O
also RB O
carried VBD O
a DT O
novel JJ O
missense NN O
mutation NN O
c NN O
. . O

A1187 NNP O
T NNP O
( -LRB- O
p NN O
. . O

E396V NN O
) -RRB- O
in IN O
exon NN O
8 CD O
of IN O
the DT O
LPL NNP O
gene NN O
. . O

Furthermore RB O
, , O
COS-1 NN O
cells NNS O
were VBD O
transfected VBN O
with IN O
lentiviruses NNS O
containing VBG O
the DT O
mutant JJ O
LPL NNP O
genes NNS O
. . O

While IN O
C310R NNP B-Var
markedly RB O
reduced VBD B-NegReg
the DT O
overall JJ O
LPL NNP B-MPA
protein NN I-MPA
level NN I-MPA
, , O
COS-1 NN O
cells NNS O
carrying VBG O
E396V RBR O
or CC O
double JJ O
mutations NNS O
contained VBD O
similar JJ O
overall JJ O
LPL NNP O
protein NN O
levels NNS O
to IN O
the DT O
wild-type JJ O
. . O

The DT O
specific JJ O
activity NN O
of IN O
the DT O
LPL NNP O
mutants NNS O
remained VBD O
at IN O
comparable JJ O
magnitude NN O
to IN O
the DT O
wild-type JJ O
. . O

However RB O
, , O
few JJ O
LPL NNP O
were VBD O
detected VBN O
in IN O
the DT O
culture NN O
medium NN O
for IN O
the DT O
mutants NNS O
, , O
suggesting VBG O
that IN O
both DT O
mutations NNS B-Var
caused VBD B-Reg
aberrant NN O
triglyceride NN B-MPA
catabolism NN I-MPA
. . O

More RBR O
specifically RB O
, , O
E396V NN B-Var
and CC O
double JJ B-Var
mutations NNS I-Var
dampened VBD B-NegReg
the DT O
transport NN B-MPA
of IN I-MPA
LPL NNP I-MPA
to IN I-MPA
the DT I-MPA
cell NN I-MPA
surface NN I-MPA
, , O
while IN O
for IN O
the DT O
C310R JJ B-Var
mutation NN O
, , O
reducing VBG B-NegReg
LPL NNP B-MPA
protein NN I-MPA
level NN I-MPA
WNT10A NN B-Gene
mutation NN B-Var
causes VBZ B-Reg
ectodermal JJ B-Disease
dysplasia NN I-Disease
by IN O
impairing VBG B-NegReg
progenitor NN B-CPA
cell NN I-CPA
proliferation NN I-CPA
and CC O
KLF4-mediated JJ B-CPA
differentiation NN I-CPA
Loss NN B-Var
of IN I-Var
function NN I-Var
in IN O
ROBO1 NNP B-Gene
is VBZ O
associated VBN B-Reg
with IN O
tetralogy NN B-Disease
of IN I-Disease
Fallot NNP I-Disease
and CC O
septal JJ B-Disease
defects NNS I-Disease
Human NNP O
Gain NNP O
of IN O
Function NN O
: : O
a DT O
Severe NNP O
and CC O
Syndromic NNP O
Immunodeficiency NNP O
. . O

Germline NNP O
heterozygous JJ O
gain-of-function NN B-PosReg
( -LRB- O
GOF NN O
) -RRB- O
mutations NNS B-Var
of IN O
NFKBIA NNP B-Gene
, , O
encoding VBG O
, , O
cause VB O
an DT O
autosomal NN O
dominant JJ O
( -LRB- O
AD NN O
) -RRB- O
form NN O
of IN O
anhidrotic JJ B-Disease
ectodermal JJ I-Disease
dysplasia NN I-Disease
with IN I-Disease
immunodeficiency NN I-Disease
( -LRB- O
EDA-ID NNP O
) -RRB- O
. . O

Fourteen CD O
unrelated JJ O
patients NNS O
have VBP O
been VBN O
reported VBN O
since IN O
the DT O
identification NN O
of IN O
the DT O
first JJ O
case NN O
in IN O
2003 CD O
. . O

All DT O
mutations NNS B-Var
enhanced VBD B-PosReg
the DT O
inhibitory JJ B-MPA
activity NN I-MPA
of IN O
, , O
by IN O
preventing VBG B-NegReg
its PRP$ O
phosphorylation NN B-MPA
on IN I-MPA
serine NN I-MPA
32 CD I-MPA
or CC I-MPA
36 CD I-MPA
and CC O
its PRP$ O
subsequent JJ O
degradation NN B-MPA
ARX NNP B-Gene
polyalanine NN B-Var
expansion NN I-Var
mutations NNS I-Var
lead VBP B-Reg
to IN I-Reg
migration NN B-CPA
impediment NN I-CPA
in IN I-CPA
the DT I-CPA
rostral JJ I-CPA
cortex NN I-CPA
coupled VBN I-CPA
with IN O
a DT O
developmental JJ B-CPA
deficit NN I-CPA
of IN I-CPA
calbindin-positive NN I-CPA
cortical JJ I-CPA
GABAergic NNP I-CPA
interneurons NNS I-CPA
. . O

The DT O
Aristaless-related NNP O
homeobox NN O
gene NN O
( -LRB- O
ARX NNP O
) -RRB- O
is VBZ O
indispensable JJ O
for IN O
interneuron NN O
development NN O
. . O

Patients NNS O
with IN O
ARX NNP O
polyalanine NN O
expansion NN O
mutations NNS O
of IN O
the DT O
first JJ O
two CD O
tracts NNS O
( -LRB- O
namely RB O
PA1 NNP O
and CC O
PA2 NNP O
) -RRB- O
suffer VBP O
from IN O
intellectual JJ O
disability NN O
of IN O
varying VBG O
severity NN O
, , O
with IN O
seizures NNS O
a DT O
frequent JJ O
comorbidity NN O
. . O

The DT O
impact NN O
of IN O
PA1 NNP O
and CC O
PA2 NNP O
mutations NNS O
on IN O
the DT O
brain NN O
development NN O
is VBZ O
unknown JJ O
, , O
hindering VBG O
the DT O
search NN O
for IN O
therapeutic JJ O
interventions NNS O
. . O

Here RB O
, , O
we PRP O
characterized VBD O
the DT O
disturbances NNS O
to IN O
cortical JJ O
interneuron NN O
development NN O
in IN O
mice NNS O
modeling VBG O
the DT O
two CD O
most RBS O
common JJ O
ARX NNP O
polyalanine NN O
expansion NN O
mutations NNS O
in IN O
human NN O
. . O

We PRP O
found VBD O
a DT O
consistent JJ O
% NN O
reduction NN O
of IN O
calbindin-positive NN O
interneurons NNS O
, , O
but CC O
not RB O
Stt+ NNP O
or CC O
Cr+ NNS O
interneurons NNS O
, , O
within IN O
the DT O
cortex NN O
of IN O
newborn JJ O
hemizygous JJ O
mice NNS O
( -LRB- O
p=0.024 NNP O
) -RRB- O
for IN O
both DT O
mutant JJ O
strains NNS O
compared VBN O
to IN O
wildtype NN O
( -LRB- O
p=0.011 NNP O
) -RRB- O
. . O

We PRP O
demonstrate VBP O
that IN O
this DT O
was VBD O
a DT O
consequence NN O
of IN O
calbindin NN O
precursor NN O
cells NNS O
being VBG O
arrested VBN O
or CC O
delayed VBN O
at IN O
the DT O
ventral JJ O
subpallium NN O
en IN O
route NN O
of IN O
tangential JJ O
migration NN O
. . O

Ex-vivo NNP O
assay NN O
validated VBD O
this DT O
migration NN O
deficit NN O
in IN O
PA1 NNP O
cells NNS O
( -LRB- O
p=0.0002 NN O
) -RRB- O
suggesting VBG O
that IN O
the DT O
defect NN O
is VBZ O
contributed VBN O
by IN O
intrinsic JJ O
loss NN O
of IN O
Arx NNP O
function NN O
within IN O
migrating VBG O
cells NNS O
. . O

Both DT O
humans NNS O
and CC O
mice NNS O
with IN O
PA1 NNP O
mutations NNS O
present JJ O
with IN O
severe JJ O
clinical JJ O
features NNS O
, , O
including VBG O
intellectual JJ O
disability NN O
and CC O
infantile JJ O
spasms NNS O
. . O

Our PRP$ O
data NNS O
further RB O
demonstrated VBD O
the DT O
pathogenic JJ O
mechanism NN O
was VBD O
robustly RB O
shared VBN O
between IN O
PA1 NNP O
and CC O
PA2 NNP O
mutations NNS O
, , O
as IN O
previously RB O
reported VBN O
including VBG O
Arx NNP O
protein NN O
reduction NN O
and CC O
overlapping NN O
transcriptome VBP O
profiles NNS O
within IN O
the DT O
developing VBG O
mouse NN O
brains NNS O
. . O

Data NNS O
from IN O
our PRP$ O
study NN O
demonstrated VBD O
that IN O
cortical JJ B-CPA
calbindin NN I-CPA
interneuron IN I-CPA
development NN B-CPA
and CC O
migration NN B-CPA
is VBZ O
negatively RB B-NegReg
affected VBN O
by IN O
ARX NNP B-Gene
polyalanine NN B-Var
expansion NN I-Var
mutations NNS I-Var
Inducible JJ O
activation NN O
of IN O
FGFR2 JJ O
in IN O
adult NN O
mice NNS O
promotes VBZ O
bone NN O
formation NN O
after IN O
bone NN O
marrow NN O
ablation NN O
. . O

Apert NNP B-Disease
syndrome NN I-Disease
is VBZ O
one CD O
of IN O
the DT O
most RBS O
severe JJ O
craniosynostoses NNS O
, , O
resulting VBG O
from IN O
gain-of-function NN B-PosReg
mutations NNS B-Var
in IN O
fibroblast JJ O
growth NN O
factor NN O
receptor NN O
2 CD O
( -LRB- O
FGFR2 JJ B-Gene
) -RRB- O
. . O

Previous JJ O
studies NNS O
have VBP O
shown VBN O
that IN O
gain-of-function NN O
mutations NNS O
of IN O
FGFR2 JJ O
( -LRB- O
S252W JJ O
or CC O
P253R NNP O
) -RRB- O
cause IN O
skull NN O
malformation NN O
of IN O
human JJ O
Apert NNP O
syndrome NN O
by IN O
affecting VBG O
both DT O
chondrogenesis NN O
and CC O
osteogenesis NN O
, , O
underscoring VBG O
the DT O
key JJ O
role NN O
of IN O
FGFR2 NN O
in IN O
bone NN O
development NN O
. . O

However RB O
, , O
the DT O
effects NNS O
of IN O
FGFR2 NN O
on IN O
bone NN O
formation NN O
at IN O
the DT O
adult NN O
stage NN O
have VBP O
not RB O
been VBN O
fully RB O
investigated VBN O
. . O

To TO O
investigate VB O
the DT O
role NN O
of IN O
FGFR2 NN O
in IN O
bone NN O
formation NN O
, , O
we PRP O
generated VBD O
mice NNS O
with IN O
tamoxifen-inducible RB O
expression NN O
of IN O
mutant JJ O
FGFR2 NNP O
( -LRB- O
P253R NNP O
) -RRB- O
at IN O
the DT O
adult NN O
stage NN O
. . O

Mechanical JJ O
bone NN O
marrow NN O
ablation NN O
( -LRB- O
BMX NNP O
) -RRB- O
was VBD O
performed VBN O
in IN O
both CC O
wild-type JJ O
and CC O
Fgfr2 NNP B-Gene
mutant JJ B-Var
( -LRB- O
MT NNP O
) -RRB- O
mice NNS O
. . O

Changes NNS O
in IN O
newly RB O
formed VBN O
trabecular NN O
bone NN O
were VBD O
assessed VBN O
by IN O
micro-computed JJ O
tomography NN O
and CC O
bone NN O
histomorphometry NN O
. . O

We PRP O
found VBD O
that IN O
MT NNP O
mice NNS O
exhibited VBD O
increased VBN B-PosReg
trabecular NN B-CPA
bone NN I-CPA
formation NN I-CPA
and CC O
decreased VBD B-NegReg
bone NN B-CPA
resorption NN I-CPA
after IN O
BMX NNP O
accompanied VBN O
with IN O
a DT O
remarkable JJ O
increase NN B-PosReg
in IN O
bone NN B-CPA
marrow NN I-CPA
stromal JJ I-CPA
cell NN I-CPA
recruitment NN B-CPA
and CC O
proliferation NN B-CPA
, , O
osteoblast NN B-CPA
proliferation NN B-CPA
and CC O
differentiation NN B-CPA
, , O
and CC O
enhanced VBN B-PosReg
Wnt/?-catenin JJ B-CPA
activity NN I-CPA
. . O

Furthermore RB O
, , O
pharmacologically RB O
inhibiting VBG O
signaling NN O
can MD O
partially RB O
reverse VB O
the DT O
increased VBN O
trabecular NN O
bone NN O
formation NN O
and CC O
decreased VBD O
bone NN O
resorption NN O
in IN O
MT NNP O
mice NNS O
after IN O
BMX NNP O
. . O

Our PRP$ O
data NNS O
demonstrate VBP O
that IN O
gain-of-function NN B-PosReg
mutation NN B-Var
in IN O
FGFR2 JJ B-Gene
exerts NNS B-MPA
a DT I-MPA
anabolic NN I-MPA
effect NN I-MPA
on IN O
trabecular JJ O
bone NN O
by IN O
promoting VBG B-PosReg
bone NN B-CPA
formation NN I-CPA
and CC O
inhibiting VBG B-NegReg
bone NN B-CPA
resorption NN I-CPA
at IN I-CPA
the DT I-CPA
adult NN I-CPA
stage NN I-CPA
Early-onset JJ B-Disease
autoimmune NN I-Disease
disease NN I-Disease
due IN O
to IN O
a DT O
heterozygous JJ O
loss-of-function NN B-NegReg
mutation NN B-Var
in IN O
TNFAIP3 NNP B-Gene
The DT O
moving VBG O
junction NN O
protein NN O
RON4 NNP O
, , O
although IN O
not RB O
critical JJ O
, , O
facilitates VBZ O
host NN O
cell NN O
invasion NN O
and CC O
stabilizes VBZ O
MJ NNP O
members NNS O
. . O

Toxoplasma NNP O
gondii NN O
is VBZ O
an DT O
obligate NN O
intracellular JJ O
parasite NN O
of IN O
phylum NN O
Apicomplexa NNP O
. . O

To TO O
facilitate VB O
high-efficiency JJ O
invasion NN O
of IN O
host NN O
cells NNS O
, , O
T. NNP O
gondii NN O
secretes VBZ O
various JJ O
proteins NNS O
related VBN O
to IN O
the DT O
moving VBG O
junction NN O
( -LRB- O
MJ NNP O
) -RRB- O
complex NN O
from IN O
rhoptries NNS O
and CC O
micronemes NNS O
into IN O
the DT O
interface NN O
between IN O
the DT O
parasite NN O
and CC O
host NN O
. . O

AMA1/RON2/4/5/8 JJ O
is VBZ O
an DT O
important JJ O
MJ NNP O
complex NN O
, , O
but CC O
its PRP$ O
mechanism NN O
of IN O
assembly NN O
remains VBZ O
unclear JJ O
. . O

In IN O
this DT O
study NN O
, , O
we PRP O
used VBD O
the DT O
CRISPR-Cas9 NNP O
system NN O
to TO O
generate VB O
a DT O
derivative NN O
of IN O
T. NNP O
gondii NN O
strain NN O
RH NNP O
with IN O
a DT O
null JJ B-Var
mutation NN I-Var
in IN O
TgRON4 DT B-Gene
, , O
thought VBD O
to TO O
be VB O
an DT O
essential JJ O
MJ NNP O
component NN O
. . O

Deficiency NN B-NegReg
of IN O
TgRON4 DT B-Protein
moderately RB O
decreased VBD B-NegReg
invasion NN B-CPA
ability NN I-CPA
relative JJ O
to IN O
that DT O
of IN O
the DT O
wild-type JJ O
parasite NN O
. . O

In IN O
addition NN O
, , O
expression NN B-MPA
of IN I-MPA
the DT I-MPA
endogenous JJ I-MPA
N-terminal NN I-MPA
fragment NN I-MPA
of IN O
RON5 NNP B-Protein
decreased VBD B-NegReg
in IN O
the DT O
mutant NN B-Var
Natural JJ O
and CC O
induced VBN O
loss NN B-NegReg
of IN I-NegReg
function NN I-NegReg
mutations NNS B-Var
in IN O
SlMBP21 NNS B-Gene
MADS-box NNPS O
gene NN O
led VBD O
to IN O
jointless-2 NNP B-CPA
phenotype NN I-CPA
Nephron NNP B-CPA
development NN I-CPA
and CC O
extrarenal JJ B-CPA
features NNS I-CPA
in IN O
a DT O
child NN O
with IN O
congenital JJ O
nephrotic JJ O
syndrome NN O
caused VBN B-Reg
by IN I-Reg
null NN O
LAMB2 NN B-Gene
mutations NNS B-Var
Exome JJ O
sequencing NN O
reveals VBZ O
independent JJ O
SGCD NNP B-Gene
deletions NNS B-Var
causing VBG B-Reg
limb NN B-Disease
girdle NN I-Disease
muscular JJ I-Disease
dystrophy NN I-Disease
in IN O
Boston NNP O
terriers NNS O
. . O

BACKGROUND NNP O
: : O
Limb-girdle NNP O
muscular JJ O
dystrophies NNS O
( -LRB- O
LGMDs NNP O
) -RRB- O
are VBP O
a DT O
heterogeneous JJ O
group NN O
of IN O
inherited VBN O
autosomal JJ O
myopathies NNS O
that WDT O
preferentially RB O
affect VBP O
voluntary JJ O
muscles NNS O
of IN O
the DT O
shoulders NNS O
and CC O
hips NNS O
. . O

LGMD NNP O
has VBZ O
been VBN O
clinically RB O
described VBN O
in IN O
several JJ O
breeds NNS O
of IN O
dogs NNS O
, , O
but CC O
the DT O
responsible JJ O
mutations NNS O
are VBP O
unknown JJ O
. . O

The DT O
clinical JJ O
presentation NN O
in IN O
dogs NNS O
is VBZ O
characterized VBN O
by IN O
marked JJ O
muscle NN O
weakness NN O
and CC O
atrophy NN O
in IN O
the DT O
shoulder NN O
and CC O
hips NNS O
during IN O
puppyhood NNS O
. . O

METHODS NNS O
: : O
Following VBG O
clinical JJ O
evaluation NN O
, , O
the DT O
identification NN O
of IN O
the DT O
dystrophic JJ O
histological JJ O
phenotype NN O
on IN O
muscle NN O
histology NN O
, , O
and CC O
demonstration NN O
of IN O
the DT O
absence NN O
of IN O
sarcoglycan-sarcospan JJ O
complex NN O
by IN O
immunostaining NN O
, , O
whole JJ O
exome JJ O
sequencing NN O
was VBD O
performed VBN O
on IN O
five CD O
Boston NNP O
terriers NNS O
: : O
one CD O
affected JJ O
dog NN O
and CC O
its PRP$ O
three CD O
family NN O
members NNS O
and CC O
one CD O
unrelated JJ O
affected JJ O
dog NN O
. . O

RESULTS NNS O
: : O
Within IN O
( -LRB- O
SGCD NNP B-Gene
) -RRB- O
, , O
a DT O
two CD O
base JJ O
pair NN O
deletion NN O
segregating VBG O
with IN O
LGMD NNP O
in IN O
the DT O
family NN O
was VBD O
discovered VBN O
, , O
and CC O
a DT O
deletion NN O
encompassing VBG O
exons NNS O
7 CD O
and CC O
8 CD O
was VBD O
found VBN O
in IN O
the DT O
unrelated JJ O
dog NN O
. . O

Both DT O
mutations NNS B-Var
are VBP O
predicted VBN O
to TO O
cause VB O
an DT O
absence NN B-NegReg
of IN O
SGCD NNP B-Gene
protein NN B-Protein
Calcium NN O
pumps NNS O
and CC O
interacting VBG O
BON1 NNP O
protein NN O
modulate VBP O
calcium NN O
signature NN O
, , O
stomatal JJ O
closure NN O
, , O
and CC O
plant NN O
immunity NN O
. . O

Calcium NNP O
signaling NN O
is VBZ O
essential JJ O
for IN O
environmental JJ O
responses NNS O
including VBG O
immune JJ O
responses NNS O
. . O

Here RB O
we PRP O
provide VBP O
evidence NN O
that IN O
the DT O
evolutionarily RB O
conserved VBN O
protein NN O
BONZAI1 NN O
( -LRB- O
BON1 NNP O
) -RRB- O
functions NNS O
together RB O
with IN O
autoinhibited VBN O
calcium NN O
ATPase NNP O
10 CD O
( -LRB- O
ACA10 NNP O
) -RRB- O
and CC O
ACA8 NNP O
to TO O
regulate VB O
calcium NN O
signals NNS O
in IN O
Arabidopsis NNP O
. . O

BON1 NNP O
is VBZ O
a DT O
plasma NN O
membrane NN O
localized JJ O
protein NN O
that WDT O
negatively RB O
regulates VBZ O
the DT O
expression NN O
of IN O
immune JJ O
receptor NN O
genes NNS O
and CC O
positively RB O
regulates VBZ O
stomatal JJ O
closure NN O
. . O

We PRP O
found VBD O
that IN O
BON1 NNP O
interacts NNS O
with IN O
the DT O
autoinhibitory JJ O
domains NNS O
of IN O
ACA10 NNP O
and CC O
ACA8 NNP O
, , O
and CC O
the DT O
aca10 JJ B-Gene
loss NN B-NegReg
of IN I-NegReg
function NN I-NegReg
( -LRB- O
LOF NNP O
) -RRB- O
mutants NNS B-Var
have VBP O
an DT O
autoimmune JJ O
phenotype NN O
similar JJ O
to IN O
that DT O
of IN O
the DT O
bon1 NNP B-Gene
LOF NNP B-NegReg
mutants NNS B-Var
. . O

Genetic JJ O
evidences NNS O
indicate VBP O
that IN O
BON1 NNP O
positively RB O
regulates VBZ O
the DT O
activities NNS O
of IN O
ACA10 NNP O
and CC O
ACA8 NNP O
. . O

Consistent JJ O
with IN O
this DT O
idea NN O
, , O
the DT O
steady JJ B-MPA
level NN I-MPA
of IN I-MPA
calcium NN I-MPA
concentration NN I-MPA
is VBZ O
increased VBN B-PosReg
in IN O
both CC O
aca10 NNP B-Gene
and CC O
bon1 IN B-Gene
mutants NNS B-Var
. . O

Most RBS O
strikingly RB O
, , O
cytosolic VBP O
calcium NN O
oscillation NN O
imposed VBN O
by IN O
external JJ O
calcium NN O
treatment NN O
was VBD O
altered VBN O
in IN O
aca10 NNP O
, , O
aca8 RB O
, , O
and CC O
bon1 IN O
mutants NNS O
in IN O
guard NN O
cells NNS O
. . O

In IN O
addition NN O
, , O
calcium NN B-CPA
and CC I-CPA
pathogen NN I-CPA
induced VBN I-CPA
stomatal JJ I-CPA
closure NN I-CPA
was VBD O
compromised VBN B-NegReg
in IN O
the DT O
aca10 NNP B-Gene
and CC O
bon1 IN B-Gene
mutants NNS B-Var
Extracellular JJ O
inhibitors NNS O
can MD O
attenuate VB O
tumorigenic NN O
Wnt NNP O
pathway NN O
activity NN O
in IN O
adenomatous JJ O
polyposis NN O
coli NNS O
mutants NNS O
: : O
Predictions NNS O
of IN O
a DT O
validated JJ O
mathematical JJ O
model NN O
. . O

BACKGROUND NNP O
: : O
Despite IN O
considerable JJ O
investigational JJ O
efforts NNS O
, , O
no DT O
method NN O
to TO O
overcome VB O
the DT O
pathogenesis NN O
caused VBN O
by IN O
loss NN O
of IN O
function NN O
( -LRB- O
LoF NN O
) -RRB- O
mutations NNS O
in IN O
tumor NN O
suppressor NN O
genes NNS O
has VBZ O
been VBN O
successfully RB O
translated VBN O
to IN O
the DT O
clinic NN O
. . O

The DT O
most RBS O
frequent JJ O
LoF IN B-NegReg
mutation NN B-Var
in IN O
human JJ O
cancers NNS O
is VBZ O
Adenomatous JJ B-Gene
polyposis NN I-Gene
coli NNS I-Gene
( -LRB- O
APC NNP O
) -RRB- O
, , O
causing VBG O
aberrant NN O
activation NN B-PosReg
of IN O
the DT O
Wnt NNP B-Pathway
pathway NN I-Pathway
. . O

In IN O
nearly RB O
all DT O
colon NN B-Disease
cancer NN I-Disease
tumors NNS I-Disease
, , O
the DT O
APC NNP B-Protein
protein NN I-Protein
is VBZ O
truncated VBN O
, , O
but CC O
still RB O
retains VBZ B-NegReg
partial JJ I-NegReg
binding JJ B-Interaction
abilities NNS B-MPA
A DT O
case NN O
of IN O
hypocholesterolemia NN B-Disease
and CC O
steatosis NN B-Disease
in IN O
a DT O
carrier NN O
of IN O
a DT O
PCSK9 NNS B-Gene
loss-of-function NN B-NegReg
mutation NN B-Var
and CC O
polymorphisms NNS O
predisposing VBG O
to TO O
nonalcoholic JJ O
fatty RB O
liver NN O
disease NN O
. . O

We PRP O
report VBP O
a DT O
new JJ O
case NN O
of IN O
hypobetalipoproteinemia NN O
in IN O
a DT O
44-year-old CD O
man NN O
of IN O
Peruvian JJ O
origin NN O
exhibiting VBG O
a DT O
heterozygous JJ O
PCSK9 NNS O
missense NN O
mutation NN O
( -LRB- O
c.946 NN B-Var
G NN O
> XX O
T NNP O
, , O
p. NN O
Gly316Cys NN O
) -RRB- O
. . O

In IN O
vitro FW O
functional JJ O
studies NNS O
demonstrated VBD O
that IN O
this DT O
mutation NN O
leads VBZ O
to IN O
a DT O
loss NN B-NegReg
of IN I-NegReg
function NN I-NegReg
of IN O
PCSK9 NNS B-Gene
on IN O
low-density JJ B-MPA
lipoprotein NN I-MPA
receptor NN I-MPA
degradation NN I-MPA
Ovarian JJ B-Protein
aromatase NN I-Protein
loss-of-function NN B-NegReg
mutant JJ B-Var
medaka NNS O
undergo VBP B-Reg
ovary JJ B-CPA
degeneration NN I-CPA
and CC O
partial JJ B-CPA
female-to-male NN I-CPA
sex NN I-CPA
reversal NN I-CPA
after IN O
puberty NN O
. . O

Although IN O
estrogens NNS O
have VBP O
been VBN O
generally RB O
considered VBN O
to TO O
play VB O
a DT O
critical JJ O
role NN O
in IN O
ovarian JJ O
differentiation NN O
in IN O
non-mammalian AFX O
vertebrates NNS O
, , O
the DT O
specific JJ O
functions NNS O
of IN O
estrogens NNS O
during IN O
ovarian JJ O
differentiation NN O
remain VBP O
unclear JJ O
. . O

We PRP O
isolated VBD O
two CD O
mutants NNS O
with IN O
premature JJ O
stops NNS O
in IN O
the DT O
ovarian JJ O
aromatase NN O
( -LRB- O
cyp19a1 NNP B-Gene
Refining NN O
genotype-phenotype NN O
correlation NN O
in IN O
syndrome NN O
through IN O
study NN O
of IN O
primary JJ O
human JJ O
fibroblasts NNS O
. . O

BACKGROUND NNP O
: : O
syndrome NN O
( -LRB- O
AS NNP O
) -RRB- O
, , O
featuring VBG O
retinal JJ O
dystrophy NN O
, , O
neuronal JJ O
deafness NN O
, , O
cardiomyopathy NN O
, , O
metabolic JJ O
syndrome NN O
, , O
and CC O
diffuse VB O
fibrosis NN O
, , O
is VBZ O
caused VBN O
by IN O
biallelic JJ O
mutations NNS O
in IN O
the DT O
centrosomal JJ O
protein NN O
ALMS1 NN O
. . O

Genotype-phenotype NNP O
correlation NN O
has VBZ O
been VBN O
suggested VBN O
without IN O
assessment NN O
of IN O
ALMS1 NN O
expression NN O
. . O

METHODS NNS O
: : O
ALMS1 VB O
expression NN O
( -LRB- O
real-time JJ O
PCR NNP O
and CC O
immunocytochemistry NN O
) -RRB- O
and CC O
cilia JJ O
formation NN O
( -LRB- O
immunocytochemistry NN O
) -RRB- O
were VBD O
assessed VBN O
in IN O
fibroblasts NNS O
from IN O
deeply RB O
phenotyped VBN O
volunteers NNS O
diagnosed VBN O
with IN O
AS NNP O
recruited VBN O
from IN O
a DT O
dedicated JJ O
AS NNP O
Service NNP O
. . O

Exome NNP O
sequencing NN O
was VBD O
used VBN O
in IN O
two CD O
participants NNS O
without IN O
convincing VBG O
biallelic JJ O
ALMS1 NN O
mutations NNS O
, , O
and CC O
BBS2 NNP O
( -LRB- O
Bardet-Biedl NNP O
syndrome NN O
2 CD O
) -RRB- O
protein NN O
expression NN O
was VBD O
assessed VBN O
in IN O
one CD O
patient NN O
with IN O
biallelic JJ O
BBS2 NNP O
mutations NNS O
. . O

Hedgehog-induced NNP O
GLI1 NNP O
expression NN O
and CC O
PDGFA NNP O
signaling NN O
was VBD O
assessed VBN O
using VBG O
quantitative JJ O
real-time JJ O
PCR NNP O
, , O
immunoblotting NN O
, , O
or CC O
immunostaining NN O
of IN O
fixed VBN O
cells NNS O
after IN O
stimulation NN O
. . O

RESULTS NNS O
: : O
In IN O
16 CD O
of IN O
the DT O
patient JJ O
cell NN O
lines NNS O
examined VBD O
, , O
ALMS1 NN B-Gene
protein NN B-Protein
was VBD O
undetectable JJ B-NegReg
( -LRB- O
14 CD O
with IN O
biallelic JJ O
loss-of-function NN B-NegReg
( -LRB- O
LoF NN O
) -RRB- O
mutations NNS B-Var
Small JJ O
chaperons NNS O
and CC O
autophagy NN O
protected VBN O
neurons NNS O
from IN O
necrotic JJ O
cell NN O
death NN O
. . O

Neuronal JJ O
necrosis NN O
occurs VBZ O
during IN O
early JJ O
phase NN O
of IN O
ischemic JJ O
insult NN O
. . O

However RB O
, , O
our PRP$ O
knowledge NN O
of IN O
neuronal JJ O
necrosis NN O
is VBZ O
still RB O
inadequate JJ O
. . O

To TO O
study VB O
the DT O
mechanism NN O
of IN O
neuronal JJ O
necrosis NN O
, , O
we PRP O
previously RB O
established VBD O
a DT O
Drosophila NNP O
genetic JJ O
model NN O
of IN O
neuronal JJ O
necrosis NN O
by IN O
calcium NN O
overloading VBG O
through IN O
expression NN O
of IN O
a DT O
constitutively RB O
opened VBN O
cation NN O
channel NN O
mutant NN O
. . O

Here RB O
, , O
we PRP O
performed VBD O
further JJ O
genetic JJ O
screens NNS O
and CC O
identified VBD O
a DT O
suppressor NN O
of IN O
neuronal JJ O
necrosis NN O
, , O
CG17259 NNP O
, , O
which WDT O
encodes VBZ O
a DT O
seryl-tRNA NN O
synthetase NN O
. . O

We PRP O
found VBD O
that IN O
loss-of-function NN B-Var
( -LRB- O
LOF NNP O
) -RRB- O
CG17259 NNP B-Gene
activated VBN B-PosReg
phosphorylation NN B-CPA
and CC O
subsequent JJ O
up-regulation JJ B-PosReg
of IN O
chaperons NNS B-CPA
( -LRB- O
Hsp26 NNP B-Protein
and CC O
Hsp27 NNP B-Protein
) -RRB- O
and CC O
autophagy NN B-CPA
. . O

Genetically RB O
, , O
down-regulation IN B-NegReg
of IN O
phosphorylation NN B-CPA
, , O
Hsp26/Hsp27 NNP B-Protein
or CC O
autophagy NN O
reduced VBD O
the DT O
protective JJ O
effect NN O
of IN O
LOF NNP O
CG17259 NNP O
, , O
indicating VBG O
they PRP O
function VBP O
downstream RB O
of IN O
CG17259 NNP O
. . O

The DT O
protective JJ O
effect NN O
of IN O
these DT O
protein NN O
degradation NN O
pathways NNS O
indicated VBD O
activation NN O
of IN O
a DT O
toxic JJ O
protein NN O
during IN O
neuronal JJ O
necrosis NN O
. . O

Our PRP$ O
data NNS O
indicated VBD O
that IN O
p53 NN O
was VBD O
likely JJ O
one CD O
such JJ O
protein NN O
, , O
because IN O
p53 NN O
was VBD O
accumulated VBN O
in IN O
the DT O
necrotic JJ O
neurons NNS O
and CC O
down-regulation IN O
of IN O
p53 NN O
rescued JJ O
necrosis NN O
. . O

In IN O
the DT O
SH-SY5Y NNP O
human JJ O
cells NNS O
, , O
tunicamycin NNS O
( -LRB- O
TM NN O
) -RRB- O
, , O
a DT O
PERK NNP O
activator NN O
, , O
promoted VBN O
transcription NN O
of IN O
hsp27 NNP O
; : O
and CC O
necrosis NN O
induced VBN O
by IN O
glutamate JJ O
could MD O
be VB O
rescued VBN O
by IN O
TM NNP O
, , O
associated VBN O
with IN O
reduced VBN O
p53 NN O
accumulation NN O
. . O

In IN O
an DT O
ischemic JJ O
stroke NN O
model NN O
in IN O
rats NNS O
, , O
p53 NN O
protein NN O
was VBD O
also RB O
increased VBN O
, , O
and CC O
TM NN O
treatment NN O
could MD O
reduce VB O
the DT O
p53 NN O
accumulation NN O
and CC O
brain NN O
damage NN O
. . O

In IN O
vivo NN O
CRISPR NNP O
screening VBG O
identifies NNS O
Ptpn2 NNP O
as IN O
a DT O
cancer NN O
immunotherapy NN O
target NN O
. . O

Immunotherapy NNP O
with IN O
PD-1 NNP O
checkpoint NN O
blockade NN O
is VBZ O
effective JJ O
in IN O
only RB O
a DT O
minority NN O
of IN O
patients NNS O
with IN O
cancer NN O
, , O
suggesting VBG O
that IN O
additional JJ O
treatment NN O
strategies NNS O
are VBP O
needed VBN O
. . O

Here RB O
we PRP O
use VBP O
a DT O
pooled VBN O
in IN O
vivo NN O
genetic JJ O
screening NN O
approach NN O
using VBG O
CRISPR-Cas9 NNP O
genome NN O
editing NN O
in IN O
transplantable JJ O
tumours NNS O
in IN O
mice NNS O
treated VBN O
with IN O
immunotherapy NN O
to TO O
discover VB O
previously RB O
undescribed VBN O
immunotherapy JJ O
targets NNS O
. . O

We PRP O
tested VBD O
2,368 CD O
genes NNS O
expressed VBN O
by IN O
melanoma NN O
cells NNS O
to TO O
identify VB O
those DT O
that WDT O
synergize VBP O
with IN O
or CC O
cause VB O
resistance NN O
to TO O
checkpoint VB O
blockade NN O
. . O

We PRP O
recovered VBD O
the DT O
known VBN O
immune JJ O
evasion NN O
molecules NNS O
PD-L1 NNP O
and CC O
CD47 NNP O
, , O
and CC O
confirmed VBD O
that IN O
defects NNS O
in IN O
signalling NN O
caused VBD O
resistance NN O
to IN O
immunotherapy NN O
. . O

Tumours NNS O
were VBD O
sensitized VBN O
to IN O
immunotherapy NN O
by IN O
deletion NN O
of IN O
genes NNS O
involved VBN O
in IN O
several JJ O
diverse JJ O
pathways NNS O
, , O
including VBG O
signalling NN O
, , O
antigen NN O
presentation NN O
and CC O
the DT O
unfolded JJ O
protein NN O
response NN O
. . O

In IN O
addition NN O
, , O
deletion NN B-Var
of IN O
the DT O
protein NN O
tyrosine NN O
phosphatase NN O
PTPN2 NN B-Gene
in IN O
tumour NN O
cells NNS O
increased VBD B-PosReg
the DT O
efficacy NN B-CPA
of IN I-CPA
immunotherapy NN I-CPA
by IN O
enhancing VBG B-PosReg
effects NNS I-MPA
on IN I-MPA
antigen NN I-MPA
presentation NN I-MPA
and CC O
growth NN B-CPA
suppression NN I-CPA
A DT O
patient NN O
with IN O
germ-line JJ O
gain-of-function NN O
PDGFRB NNP O
p XX O
. . O

N666H JJ O
mutation NN O
and CC O
marked JJ O
clinical JJ O
response NN O
to IN O
imatinib NNS O
. . O

PurposeHeterozygous JJ O
germ-line JJ O
activating VBG O
mutations NNS B-Var
in IN O
PDGFRB NNP B-Gene
cause IN B-Reg
Kosaki NNP B-Disease
and CC I-Disease
Penttinen NNP I-Disease
syndromes NNS I-Disease
and CC O
myofibromatosis NN B-Disease
. . O

We PRP O
describe VBP O
a DT O
10-year-old CD O
child NN O
with IN O
a DT O
germ-line JJ O
PDGFRB NNP B-Gene
p XX B-Var
. . O

N666H JJ O
mutation NN O
who WP O
responded VBD B-MPA
to IN I-MPA
the DT I-MPA
tyrosine JJ I-MPA
kinase NN I-MPA
inhibitor NN I-MPA
imatinib NNS I-MPA
by IN O
inhibition NN B-NegReg
of IN O
PDGFRB.MethodsThe NNP B-Gene
Genetic JJ O
Diseases NNS O
of IN O
PIEZO1 NN O
and CC O
PIEZO2 NNP O
Dysfunction NNP O
. . O

Mutations NNPS O
in IN O
the DT O
genes NNS O
encoding VBG O
the DT O
mechanosensitive JJ O
cation NN O
channels NNS O
PIEZO1 NN O
and CC O
PIEZO2 NNS O
are VBP O
responsible JJ O
for IN O
multiple JJ O
hereditary JJ O
human JJ O
diseases NNS O
. . O

Loss-of-function NN B-NegReg
mutations NNS B-Var
in IN O
the DT O
human JJ O
PIEZO1 NN B-Gene
gene NN O
cause NN O
autosomal NN B-Disease
recessive JJ I-Disease
congenital JJ I-Disease
lymphatic JJ I-Disease
dysplasia NN I-Disease
. . O

Gain-of-function NN B-PosReg
mutations NNS B-Var
in IN O
the DT O
human JJ O
PIEZO1 NN B-Gene
gene NN O
cause IN O
the DT O
autosomal NN B-Disease
dominant JJ I-Disease
hemolytic JJ I-Disease
anemia NN I-Disease
, , O
hereditary JJ B-Disease
xerocytosis NN I-Disease
( -LRB- O
also RB O
known VBN O
as IN O
dehydrated VBN B-Disease
stomatocytosis NN I-Disease
) -RRB- O
. . O

Loss-of-function NN B-NegReg
mutations NNS B-Var
in IN O
the DT O
human NN O
PIEZO2 NNP B-Gene
gene NN O
cause VBP O
an DT O
autosomal NN B-Disease
recessive JJ I-Disease
syndrome NN I-Disease
of IN I-Disease
muscular JJ I-Disease
atrophy NN I-Disease
with IN O
perinatal JJ O
respiratory JJ O
distress NN O
, , O
arthrogryposis NN B-Disease
, , O
and CC O
scoliosis NN B-Disease
. . O

Gain-of-function NN B-PosReg
mutations NNS B-Var
in IN O
the DT O
human NN O
PIEZO2 NNP B-Gene
gene NN O
cause VBP O
three CD O
clinical JJ O
types NNS O
of IN O
autosomal NN B-Disease
dominant JJ I-Disease
distal JJ I-Disease
arthrogryposis NN I-Disease
Differential JJ O
calcium NN O
sensitivity NN O
in IN O
NaV NNP O
1.5 CD O
mixed JJ O
syndrome NN O
mutants NNS O
. . O

KEY JJ O
POINTS NNS O
: : O
SCN5a NN B-Gene
mutations NNS B-Var
may MD O
express VB O
gain-of-function NN B-PosReg
( -LRB- O
Long NNP B-Disease
QT NNP I-Disease
Syndrome-3 NNP I-Disease
) -RRB- O
, , O
loss-of-function NN B-NegReg
( -LRB- O
Brugada NNP B-Disease
Syndrome NNP I-Disease
1 CD I-Disease
D242N NNP O
, , O
a DT O
KV7.1 NNP O
LQTS NNP O
mutation NN O
uncovers VBZ O
a DT O
key JJ O
residue NN O
for IN O
IKs NNS O
voltage NN O
dependence NN O
. . O

KV7.1 NNP O
and CC O
KCNE1 NNP O
co-assemble NN O
to TO O
give VB O
rise NN O
to IN O
the DT O
IKs NNS O
current JJ O
, , O
one CD O
of IN O
the DT O
most RBS O
important JJ O
repolarizing NN O
currents NNS O
of IN O
the DT O
cardiac JJ O
action NN O
potential NN O
. . O

Its PRP$ O
relevance NN O
is VBZ O
underscored VBN O
by IN O
the DT O
identification NN O
of IN O
> XX O
500 CD O
mutations NNS B-Var
in IN O
KV7.1 NNP B-Gene
and CC O
, , O
at IN O
least JJS O
, , O
36 CD O
in IN O
KCNE1 NNP B-Gene
, , O
that WDT O
cause VBP B-Reg
Long NNP B-Disease
QT NNP I-Disease
Syndrome NNP I-Disease
( -LRB- O
LQTS NNP O
) -RRB- O
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
characterize VB O
the DT O
biophysical JJ O
and CC O
cellular JJ O
consequences NNS O
of IN O
the DT O
D242N JJ B-Var
KV7.1 NNP B-Gene
mutation NN O
associated VBN B-Reg
with IN O
the DT O
LQTS NNP B-Disease
. . O

The DT O
mutation NN B-Var
is VBZ O
located VBN O
in IN O
the DT O
S4 NN O
transmembrane NN O
segment NN O
, , O
within IN O
the DT O
voltage NN O
sensor NN O
of IN O
the DT O
KV7.1 NNP O
channel NN O
, , O
disrupting VBG B-NegReg
the DT O
conserved JJ B-MPA
charge NN I-MPA
balance NN I-MPA
of IN I-MPA
this DT I-MPA
region NN I-MPA
. . O

Perforated VBN O
patch-clamp NN O
experiments NNS O
show VBP O
that IN O
, , O
unexpectedly RB O
, , O
the DT O
mutation NN B-Var
did VBD O
not RB O
disrupt VB O
the DT O
voltage-dependent NN O
activation NN O
but CC O
it PRP O
removed VBD B-NegReg
the DT O
inactivation NN B-MPA
and CC O
slowed VBD B-NegReg
the DT O
activation NN B-MPA
kinetics NNS I-MPA
of IN O
D242N NNP B-MPA
KV7.1 NNP I-MPA
channels NNS I-MPA
. . O

Biotinylation NN O
of IN O
cell-surface NN O
protein NN O
and CC O
co-immunoprecipitation NN O
experiments NNS O
revealed VBD O
that IN O
neither DT O
plasma NN O
membrane NN O
targeting NN O
nor CC O
co-assembly NN O
between IN O
KV7.1 NNP O
and CC O
KCNE1 NNP O
was VBD O
altered VBN O
by IN O
the DT O
mutation NN O
. . O

However RB O
, , O
the DT O
association NN O
of IN O
D242N NNP O
KV7.1 NNP O
with IN O
KCNE1 NNP O
strongly RB O
shifted VBD O
the DT O
voltage NN O
dependence NN O
of IN O
activation NN O
to IN O
more JJR O
depolarized JJ O
potentials NNS O
( -LRB- O
+ SYM O
50mV CD O
) -RRB- O
, , O
hindering VBG O
IKs NNS O
current JJ O
at IN O
physiologically RB O
relevant JJ O
membrane JJ O
potentials NNS O
. . O

Both DT O
functional JJ O
and CC O
computational JJ O
analysis NN O
suggest VBP O
that IN O
the DT O
clinical JJ O
phenotype NN O
of IN O
the DT O
LQTS NNP O
patients NNS O
carrying VBG O
the DT O
D242N NN B-Var
mutation NN O
is VBZ O
due JJ O
to IN O
impaired JJ B-NegReg
action NN B-MPA
potential JJ I-MPA
adaptation NN I-MPA
to TO I-MPA
exercise VB I-MPA
and CC O
, , O
in IN O
particular JJ O
, , O
to TO O
increase VB B-PosReg
in IN O
heart NN B-MPA
rate NN I-MPA
A DT O
Gene NN O
Implicated VBN O
in IN O
Activation NNP O
of IN O
Retinoic NNP O
Acid NNP O
Receptor NNP O
Targets NNP O
is VBZ O
a DT O
Novel NNP O
Renal NNP O
Agenesis NNP O
Gene NNP O
in IN O
Humans NNP O
. . O

Renal JJ B-Disease
agenesis NN I-Disease
( -LRB- O
RA NNP O
) -RRB- O
is VBZ O
one CD O
of IN O
the DT O
more RBR O
extreme JJ O
examples NNS O
of IN O
congenital JJ O
anomalies NNS O
of IN O
the DT O
kidney NN O
and CC O
urinary JJ O
tract NN O
( -LRB- O
CAKUT NNP O
) -RRB- O
. . O

Bilateral JJ O
renal JJ O
agenesis NN O
is VBZ O
almost RB O
invariably RB O
fatal JJ O
at IN O
birth NN O
, , O
and CC O
unilateral JJ O
renal JJ O
agenesis NN O
can MD O
lead VB O
to IN O
future JJ O
health NN O
issues NNS O
including VBG O
end NN O
stage NN O
renal JJ O
disease NN O
. . O

Genetic JJ O
investigations NNS O
have VBP O
identified VBN O
several JJ O
gene NN O
variants NNS B-Var
which WDT O
cause VBP B-Reg
RA NNP B-Disease
, , O
including VBG O
EYA1 NNP O
, , O
LHX1 NNP O
, , O
and CC O
WT1 NNP O
However RB O
, , O
whereas IN O
compound NN O
null NN O
mutations NNS O
of IN O
genes NNS O
encoding VBG O
and CC O
retinoic NN O
acid NN O
receptors NNS O
( -LRB- O
RARs NNS O
) -RRB- O
cause IN O
RA NNP O
in IN O
mice NNS O
, , O
to IN O
date NN O
there EX O
have VBP O
been VBN O
no DT O
reports NNS O
of IN O
variants NNS O
in IN O
RAR NNP O
genes NNS O
causing VBG O
RA NNP O
in IN O
humans NNS O
. . O

In IN O
this DT O
study NN O
, , O
we PRP O
carried VBD O
out RP O
whole JJ O
exome NN O
sequence NN O
analysis NN O
of IN O
two CD O
families NNS O
showing VBG O
inheritance NN O
of IN O
an DT O
RA NNP O
phenotype NN O
, , O
and CC O
in IN O
both DT O
identified VBD O
a DT O
single JJ O
candidate NN O
gene NN O
, , O
GREB1L NNP O
Analysis NNP O
of IN O
a DT O
zebrafish JJ O
greb1l NNS O
loss-of-function NN B-NegReg
mutant JJ B-Var
revealed VBN O
defects NNS O
in IN O
the DT O
pronephric JJ B-MPA
kidney NN I-MPA
just RB I-MPA
prior RB I-MPA
to IN I-MPA
death NN I-MPA
, , O
and CC O
F0 DT O
CRISPR NNP O
/ SYM O
Cas9 PRP$ O
mutagenesis NN B-Var
of IN O
Greb1l NNP O
in IN O
the DT O
mouse NN O
revealed VBD B-Reg
kidney NN B-MPA
agenesis NN I-MPA
phenotypes NNS I-MPA
Equivalent JJ O
missense NN B-Var
variant NN I-Var
in IN O
the DT O
FOXP2 NN B-Gene
and CC O
FOXP1 NN B-Gene
transcription NN O
factors NNS O
causes VBZ B-Reg
distinct JJ O
neurodevelopmental JJ B-Disease
disorders NNS I-Disease
. . O

The DT O
closely RB O
related JJ O
paralogues NNS O
FOXP2 NN O
and CC O
FOXP1 NN O
encode JJ O
transcription NN O
factors NNS O
with IN O
shared VBN O
functions NNS O
in IN O
the DT O
development NN O
of IN O
many JJ O
tissues NNS O
, , O
including VBG O
the DT O
brain NN O
. . O

However RB O
, , O
while IN O
mutations NNS B-Var
in IN O
FOXP2 NN B-Gene
lead NN B-Reg
to IN I-Reg
a DT O
speech NN O
/ SYM O
language NN O
disorder NN O
characterized VBN O
by IN O
childhood NN B-Disease
apraxia NN I-Disease
of IN I-Disease
speech NN I-Disease
( -LRB- O
CAS NNP O
) -RRB- O
, , O
the DT O
clinical JJ O
profile NN O
of IN O
FOXP1 NN B-Gene
variants NNS B-Var
includes VBZ B-Reg
a DT O
broader JJR O
neurodevelopmental JJ O
phenotype NN O
with IN O
global JJ B-Disease
developmental JJ I-Disease
delay NN I-Disease
, , O
intellectual JJ B-Disease
disability NN I-Disease
, , O
and CC O
speech NN B-Disease
/ SYM I-Disease
Novel JJ O
PRPS1 JJ O
gain-of-function VB O
mutation NN O
in IN O
a DT O
patient NN O
with IN O
congenital JJ O
hyperuricemia NN O
and CC O
facial JJ O
anomalies NNS O
. . O

Phosphoribosylpyrophosphate NNP O
synthetase NN O
( -LRB- O
PRPPS NNP O
) -RRB- O
superactivity NN O
( -LRB- O
OMIM NNP O
300661 CD O
) -RRB- O
is VBZ O
a DT O
rare JJ O
inborn JJ O
error NN O
of IN O
purine NN O
metabolism NN O
that WDT O
is VBZ O
caused VBN O
by IN O
gain-of-function NN O
mutations NNS O
in IN O
the DT O
X-chromosomal NN O
gene NN O
PRPS1 NN O
( -LRB- O
Xq22.3 NNP O
) -RRB- O
. . O

Clinical JJ O
characteristics NNS O
include VBP O
congenital JJ O
hyperuricemia NN O
and CC O
hyperuricosuria NN O
, , O
gouty NN O
arthritis NN O
, , O
urolithiasis NN O
, , O
developmental JJ O
delay NN O
, , O
hypotonia NN O
, , O
recurrent JJ O
infections NNS O
, , O
short JJ O
stature NN O
, , O
and CC O
hearing NN O
loss NN O
. . O

Only RB O
eight CD O
families NNS O
with IN O
PRPPS NNP O
superactivity NN O
and CC O
PRPS1 JJ O
gain-of-function VB O
mutations NNS O
have VBP O
been VBN O
reported VBN O
to IN O
date NN O
. . O

We PRP O
report VBP O
on IN O
a DT O
7-year-old JJ O
boy NN O
with IN O
congenital JJ O
hyperuricemia NN O
, , O
urolithiasis NN O
, , O
developmental JJ O
delay NN O
, , O
short JJ O
stature NN O
, , O
hypospadias NNS O
, , O
and CC O
facial JJ O
dysmorphisms NNS O
. . O

His PRP$ O
mother NN O
also RB O
suffered VBD O
from IN O
hyperuricemia NN O
that WDT O
was VBD O
diagnosed VBN O
at IN O
age NN O
13 CD O
years NNS O
. . O

A DT O
novel JJ O
PRPS1 JJ O
missense NN O
mutation NN O
( -LRB- O
c.573G NN O
> XX O
C NN O
, , O
p.[Leu191Phe NNP O
] -RRB- O
) -RRB- O
was VBD O
detected VBN O
in IN O
the DT O
proband NN O
and CC O
his PRP$ O
mother NN O
. . O

Enzyme NN O
activity NN O
analysis NN O
confirmed VBD O
superactivity NN O
of IN O
PRPP NNP O
synthetase NN O
. . O

Analysis NN O
of IN O
the DT O
crystal NN O
structure NN O
of IN O
human JJ O
PRPPS NNP O
suggests VBZ O
that IN O
the DT O
Leu191Phe NNP B-Gene
mutation NN B-Var
affects VBZ B-Reg
the DT O
architecture NN B-MPA
of IN O
both CC O
allosteric JJ O
sites NNS O
, , O
thereby RB O
preventing VBG B-NegReg
the DT O
allosteric JJ B-MPA
inhibition NN I-MPA
of IN O
the DT O
enzyme NN B-Enzyme
Naturally-Segregating RB B-Var
Variation NNP I-Var
at IN O
Ugt86Dd NNP B-Gene
Contributes NNP B-PosReg
to IN O
Nicotine NNP B-MPA
Resistance NNP I-MPA
in IN I-MPA
Drosophila NNP I-MPA
melanogaster NN I-MPA
. . O

Identifying VBG O
the DT O
sequence NN O
polymorphisms VBZ O
underlying VBG O
complex JJ O
trait NN O
variation NN O
is VBZ O
a DT O
key JJ O
goal NN O
of IN O
genetics NNS O
research NN O
, , O
since IN O
knowing VBG O
the DT O
precise JJ O
causative JJ O
molecular JJ O
events NNS O
allows VBZ O
insight NN O
into IN O
the DT O
pathways NNS O
governing VBG O
trait NN O
variation NN O
. . O

Genetic JJ O
analysis NN O
of IN O
complex JJ O
traits NNS O
in IN O
model NN O
systems NNS O
regularly RB O
starts VBZ O
by IN O
constructing VBG O
QTL NNP O
maps NNS O
, , O
but CC O
generally RB O
fails VBZ O
to TO O
identify VB O
causative JJ O
sequence NN O
polymorphisms NNS O
. . O

Previously RB O
we PRP O
mapped VBD O
a DT O
series NN O
of IN O
QTL NNP O
contributing VBG O
to IN O
resistance NN O
to TO O
nicotine VB O
in IN O
a DT O
Drosophila NNP O
melanogaster NN O
multiparental JJ O
mapping NN O
resource NN O
, , O
and CC O
here RB O
use VB O
a DT O
battery NN O
of IN O
functional JJ O
tests NNS O
to TO O
resolve VB O
QTL NNP O
to IN O
the DT O
molecular JJ O
level NN O
. . O

One CD O
large-effect JJ O
QTL NNP O
resided VBD O
over IN O
a DT O
cluster NN O
of IN O
UDP-glucuronosyltransferases NNP O
, , O
and CC O
quantitative JJ O
complementation NN O
tests NNS O
using VBG O
deficiencies NNS O
eliminating VBG O
subsets NNS O
of IN O
these DT O
detoxification NN O
genes NNS O
revealed VBD O
allelic JJ O
variation NN O
impacting VBG O
resistance NN O
. . O

RNAseq NNP O
showed VBD O
that IN O
Ugt86Dd NNP O
had VBD O
significantly RB O
higher JJR O
expression NN O
in IN O
genotypes NNS O
that WDT O
are VBP O
more RBR O
resistant JJ O
to IN O
nicotine VB O
, , O
and CC O
anterior NN O
midgut-specific NN O
RNAi NNPS O
of IN O
this DT O
gene NN O
reduced VBN O
resistance NN O
. . O

We PRP O
discovered VBD O
a DT O
segregating VBG O
22-bp CD O
frameshift NN B-Var
deletion NN I-Var
in IN O
Ugt86Dd NNP B-Gene
, , O
and CC O
accounting VBG O
for IN O
the DT O
InDel NNP O
during IN O
mapping VBG O
largely RB O
eliminates VBZ B-NegReg
the DT O
QTL NNP B-MPA
, , O
implying VBG O
the DT O
event NN O
explains VBZ O
the DT O
bulk NN O
of IN O
the DT O
effect NN O
of IN O
the DT O
mapped VBN O
locus NN O
. . O

CRISPR NNP O
/ NFP O
Cas9 PRP$ O
editing VBG O
a DT O
relatively RB O
resistant JJ O
genotype NN O
to TO O
generate VB O
lesions NNS B-Var
in IN O
Ugt86Dd NNP B-Gene
that WDT O
recapitulate VBP O
the DT O
naturally-occurring RB O
putative JJ O
loss-of-function NN B-NegReg
allele NN O
leads VBZ O
to IN O
a DT O
large JJ O
reduction NN B-NegReg
in IN O
resistance NN B-MPA
Sequence NN B-Var
exchange NN I-Var
between IN O
R NN B-Gene
genes NNS O
converts VBZ B-Reg
virus NN O
resistance NN O
into IN O
nematode NN B-MPA
resistance NN I-MPA
, , O
and CC O
vice RB O
versa RB O
. . O

Plants NNS O
have VBP O
evolved VBN O
a DT O
limited JJ O
repertoire NN O
of IN O
NB-LRR NN O
disease NN O
resistance NN O
( -LRB- O
R NN O
) -RRB- O
genes NNS O
to TO O
protect VB O
themselves PRP O
against IN O
a DT O
myriad NN O
of IN O
pathogens NNS O
. . O

This DT O
limitation NN O
is VBZ O
thought VBN O
to TO O
be VB O
counterbalanced VBN O
by IN O
the DT O
rapid JJ O
evolution NN O
of IN O
NB-LRR NN O
proteins NNS O
, , O
as IN O
only RB O
few JJ O
sequence NN O
changes NNS B-Var
have VBP O
been VBN O
shown VBN O
to TO O
be VB O
sufficient JJ O
to TO O
alter VB B-Reg
resistance NN B-MPA
specificities NNS I-MPA
towards IN I-MPA
novel JJ I-MPA
strains NNS I-MPA
of IN I-MPA
a DT I-MPA
pathogen NN I-MPA
. . O

However RB O
, , O
little JJ O
is VBZ O
known VBN O
about IN O
the DT O
flexibility NN O
of IN O
NB-LRR NN O
genes NNS O
to TO O
switch VB O
resistance NN O
specificities NNS O
between IN O
phylogenetically RB O
unrelated JJ O
pathogens NNS O
. . O

To TO O
investigate VB O
this DT O
, , O
we PRP O
created VBD O
domain NN O
swaps NNS O
between IN O
the DT O
close JJ O
homologs NNS O
Gpa2 NNS O
and CC O
Rx1 NN O
, , O
which WDT O
confer VBP O
resistance NN O
in IN O
potato NN O
to IN O
the DT O
cyst NN O
nematode NN O
Globodera NNP O
pallida NN O
and CC O
Potato NNP O
virus NN O
X NN O
( -LRB- O
PVX NNP O
) -RRB- O
, , O
respectively RB O
. . O

The DT O
genetic JJ O
fusion NN O
of IN O
the DT O
CC-NB-ARC NN O
of IN O
Gpa2 CD O
with IN O
the DT O
LRR NNP O
of IN O
Rx1 NN O
( -LRB- O
Gpa2CN NN O
/ SYM O
Rx1L NN O
) -RRB- O
resulted VBD O
in IN O
autoactivity NN O
, , O
but CC O
lowering VBG O
the DT O
protein NN O
levels NNS O
restored VBD O
its PRP$ O
specific JJ O
activation NN O
response NN O
including VBG O
extreme JJ O
resistance NN O
to IN O
PVX NNP O
in IN O
potato NN O
shoots NNS O
. . O

The DT O
reciprocal JJ O
construct NN O
( -LRB- O
Rx1CN NNP O
/ SYM O
Gpa2L NNP O
) -RRB- O
showed VBD O
a DT O
loss-of-function NN O
phenotype NN O
, , O
but CC O
exchange NN B-Var
of IN O
the DT O
first JJ O
3 CD O
LRR NNP O
repeats NNS O
of IN O
Rx1 NN B-Gene
was VBD O
sufficient JJ O
to TO O
regain VB B-PosReg
a DT O
wild JJ B-MPA
type NN I-MPA
resistance NN I-MPA
response NN I-MPA
to IN I-MPA
G. NNP I-MPA
pallida NN I-MPA
in IN I-MPA
the DT I-MPA
roots NNS I-MPA
. . O

These DT O
data NNS O
demonstrate VBP O
that IN O
exchanging VBG B-Var
the DT O
recognition NN O
moiety NN O
in IN O
the DT O
LRR NNP O
is VBZ O
sufficient JJ O
to TO O
convert VB B-Reg
extreme JJ O
virus NN O
resistance NN O
in IN O
the DT O
leaves NNS O
into IN O
mild JJ B-MPA
nematode NN I-MPA
resistance NN I-MPA
in IN I-MPA
the DT I-MPA
roots NNS I-MPA
Lethal JJ O
digenic JJ O
mutations NNS B-Var
in IN O
the DT O
K(+ NNP O
) -RRB- O
channels NNS O
Kir4.1 NNP O
( -LRB- O
KCNJ10 NNP B-Gene
) -RRB- O
and CC O
SLACK NNP O
( -LRB- O
KCNT1 NNP B-Gene
) -RRB- O
associated VBN B-Reg
with IN O
severe-disabling JJ O
seizures NNS B-Disease
and CC O
neurodevelopmental JJ B-Disease
delay NN I-Disease
. . O

A DT O
2-year-old JJ O
boy NN O
presented VBD O
profound JJ O
developmental JJ O
delay NN O
, , O
failure NN O
to TO O
thrive VB O
, , O
ataxia NN O
, , O
hypotonia NN O
and CC O
tonic-clonic NN O
seizures NNS O
that WDT O
caused VBD O
the DT O
death NN O
of IN O
the DT O
patient NN O
. . O

Targeted VBN O
and CC O
whole-exome JJ O
sequencing NN O
revealed VBD O
two CD O
heterozygous JJ O
missense NN O
variants NNS O
: : O
a DT O
novel JJ O
mutation NN O
in IN O
KCNJ10 NNP O
gene NN O
that IN O
encodes NNS O
for IN O
the DT O
inwardly-rectifying RB O
K(+ NNP O
) -RRB- O
channel NN O
Kir4.1 NNP O
and CC O
another DT O
previously RB O
characterized VBN O
mutation NN O
in IN O
KCNT1 NNP O
that WDT O
encodes NNS O
for IN O
the DT O
Na(+)-activated NNP O
K(+ NNP O
) -RRB- O
channel NN O
known VBN O
as IN O
Slo2.2 NNPS O
or CC O
SLACK NNP O
. . O

The DT O
objectives NNS O
of IN O
this DT O
study NN O
were VBD O
to TO O
perform VB O
the DT O
clinical JJ O
and CC O
genetic JJ O
characterization NN O
of IN O
the DT O
proband NN O
and CC O
his PRP$ O
family NN O
and CC O
to TO O
examine VB O
the DT O
functional JJ O
consequence NN O
of IN O
the DT O
Kir4.1 NNP O
mutation NN O
. . O

The DT O
mutant JJ O
and CC O
wild-type JJ O
KCNJ10 NNP O
constructs NNS O
were VBD O
generated VBN O
and CC O
heterologously RB O
expressed VBN O
in IN O
Xenopus NNP O
laevis NN O
oocytes NNS O
, , O
and CC O
whole-cell JJ O
K(+ NNP O
) -RRB- O
currents NNS O
were VBD O
measured VBN O
using VBG O
the DT O
two-electrode CD O
voltage-clamp NN O
technique NN O
. . O

The DT O
KCNJ10 NNP B-Gene
mutation NN B-Var
c.652C NN O
> XX O
T NNP O
resulted VBD B-Reg
in IN I-Reg
a DT O
p NN O
. . O

L218F JJ O
substitution NN B-Var
at IN O
a DT O
highly RB O
conserved JJ O
residue JJ O
site NN O
. . O

Wild-type JJ O
KCNJ10 NNP O
expression NN O
yielded VBD O
robust JJ O
Kir NNP O
currents NNS O
, , O
while IN O
currents NNS O
from IN O
oocytes NNS O
expressing VBG O
the DT O
mutation NN O
were VBD O
reduced VBN O
. . O

Western JJ O
Blot NNP O
analysis NN O
revealed VBD O
reduced JJ B-NegReg
protein NN B-MPA
expression NN I-MPA
by IN O
the DT O
mutation NN B-Var
. . O

Kir5.1 NN O
subunits VBZ O
display NN O
selective JJ O
heteromultimerization NN O
with IN O
Kir4.1 NNP O
constituting VBG O
channels NNS O
with IN O
unique JJ O
kinetics NNS O
. . O

The DT O
effect NN O
of IN O
the DT O
mutation NN O
on IN O
Kir4.1/5.1 NNP O
channel NN O
activity NN O
was VBD O
twofold JJ O
: : O
a DT O
reduction NN O
in IN O
current JJ O
amplitudes NNS O
and CC O
an DT O
increase NN O
in IN O
the DT O
pH-dependent VBN O
inhibition NN O
. . O

We PRP O
thus RB O
report VBP O
a DT O
novel JJ O
loss-of-function NN B-NegReg
mutation NN B-Var
in IN O
Kir4.1 NNP O
found VBD O
in IN O
a DT O
patient NN O
with IN O
a DT O
co-exiting NN O
mutation NN B-Var
in IN O
SLACK NNP O
channels NNS O
that WDT O
results VBZ B-Reg
in IN I-Reg
a DT O
fatal JJ B-Disease
disease NN I-Disease
Allelic NNP O
Complexity NNP O
in IN O
Long NNP O
QT NNP O
Syndrome NN O
: : O
A DT O
Family-Case NNP O
Study NNP O
. . O

Congenital JJ O
long JJ B-Disease
QT NNP I-Disease
syndrome NN I-Disease
( -LRB- O
LQTS NNP O
) -RRB- O
is VBZ O
associated VBN O
with IN O
high JJ O
genetic JJ O
and CC O
allelic JJ O
heterogeneity NN O
. . O

In IN O
some DT O
cases NNS O
, , O
more JJR O
than IN O
one CD O
genetic JJ O
variant NN O
is VBZ O
identified VBN O
in IN O
the DT O
same JJ O
( -LRB- O
compound NN O
heterozygosity NN O
) -RRB- O
or CC O
different JJ O
( -LRB- O
digenic JJ O
heterozygosity NN O
) -RRB- O
genes NNS O
, , O
and CC O
subjects NNS O
with IN O
multiple JJ O
pathogenic JJ O
mutations NNS O
may MD O
have VB O
a DT O
more RBR O
severe JJ O
disease NN O
. . O

Standard-of-care JJ O
clinical JJ O
genetic JJ O
testing NN O
for IN O
this DT O
and CC O
other JJ O
arrhythmia NN O
susceptibility NN O
syndromes NNS O
improves VBZ O
the DT O
identification NN O
of IN O
complex JJ O
genotypes NNS O
. . O

Therefore RB O
, , O
it PRP O
is VBZ O
important JJ O
to TO O
distinguish VB O
between IN O
pathogenic JJ O
mutations NNS O
and CC O
benign JJ O
rare JJ O
variants NNS O
. . O

We PRP O
identified VBD O
four CD O
genetic JJ O
variants NNS O
( -LRB- O
KCNQ1-p NNP O
. . O

R583H NNP O
, , O
KCNH2-p NNP O
. . O

C108Y NN O
, , O
KCNH2-p NNP O
. . O

K897 NN O
T NNP O
, , O
and CC O
KCNE1-p NNP O
. . O

G38S NNP O
) -RRB- O
in IN O
an DT O
LQTS NNP O
family NN O
. . O

On IN O
the DT O
basis NN O
of IN O
in IN O
silico NN O
analysis NN O
, , O
clinical JJ O
data NNS O
from IN O
our PRP$ O
family NN O
, , O
and CC O
the DT O
evidence NN O
from IN O
previous JJ O
studies NNS O
, , O
we PRP O
analyzed VBD O
two CD O
mutated VBN O
channels NNS O
, , O
KCNQ1-p NNP O
. . O

R583H NNP O
and CC O
KCNH2-p NNP O
. . O

C108Y NN O
, , O
using VBG O
the DT O
whole-cell JJ O
patch NN O
clamp NN O
technique NN O
. . O

We PRP O
found VBD O
that IN O
KCNQ1-p NNP O
. . O

R583H NNP O
was VBD O
not RB O
associated VBN O
with IN O
a DT O
severe JJ O
functional JJ O
impairment NN O
, , O
whereas IN O
KCNH2-p NNP B-Gene
. . O

C108Y NN O
, , O
a DT O
novel JJ O
variant NN O
, , O
encoded VBD O
a DT O
non-functional AFX O
channel NN O
that WDT O
exerts NNS O
dominant-negative JJ O
effects NNS O
on IN O
the DT O
wild-type JJ O
. . O

Notably RB O
, , O
the DT O
common JJ O
variants NNS O
KCNH2-p NNP O
. . O

K897 NN O
T NNP O
and CC O
KCNE1-p NNP O
. . O

G38S NNP O
were VBD O
previously RB O
reported VBN O
to TO O
produce VB O
more RBR O
severe JJ O
phenotypes NNS O
when WRB O
combined VBN O
with IN O
disease-causing NN O
alleles NNS O
. . O

Our PRP$ O
results NNS O
indicate VBP O
that IN O
the DT O
novel JJ O
KCNH2-C108Y NN O
variant NN O
can MD O
be VB O
a DT O
pathogenic JJ O
LQTS NNP O
mutation NN O
, , O
whereas IN O
KCNQ1-p NNP O
. . O

R583H NNP O
, , O
KCNH2-p NNP O
. . O

K897 NN O
T NNP O
, , O
and CC O
KCNE1-p NNP O
. . O

G38S NNP O
could MD O
be VB O
LQTS NNP O
modifiers NNS O
. . O

POSITIVE NNP O
REGULATOR NNP O
OF IN O
IRON JJ O
HOMEOSTASIS NNP O
1 CD O
( -LRB- O
OsPRI1 NFP O
) -RRB- O
positively RB O
regulates VBZ O
iron NN O
homeostasis NN O
in IN O
rice NN O
. . O

OsHRZ1 NN O
is VBZ O
a DT O
potential JJ O
iron-binding NN O
sensor NN O
. . O

However RB O
, , O
it PRP O
is VBZ O
unclear JJ O
how WRB O
OsHRZ1 JJ O
transmits NNS O
signals NNS O
. . O

In IN O
this DT O
study NN O
, , O
we PRP O
reveal VBP O
that IN O
OsPRI1 NN O
interacts NNS O
with IN O
OsHRZ1 NN O
. . O

A DT O
loss-of-function NN B-NegReg
mutation NN B-Var
to IN O
OsPRI1 NNP B-Gene
increased VBD B-PosReg
the DT O
sensitivity NN B-MPA
of IN I-MPA
plants NNS I-MPA
to IN I-MPA
Fe-deficient NNP I-MPA
conditions NNS I-MPA
and CC O
downregulated VBD B-NegReg
the DT O
expression NN B-MPA
of IN I-MPA
Fe-deficiency-responsive NNP I-MPA
genes NNS I-MPA
. . O

Yeast NN O
one-hybrid CD O
and CC O
electrophoretic JJ O
mobility NN O
shift NN O
assay JJ O
results NNS O
suggested VBD O
that IN O
OsPRI1 DT O
binds NNS O
to IN O
the DT O
OsIRO2 NNS O
and CC O
OsIRO3 NN O
promoters NNS O
. . O

In IN O
vitro FW O
ubiquitination NN O
experiments NNS O
indicated VBD O
that IN O
OsPRI1 NN O
is VBZ O
ubiquitinated VBN O
by IN O
OsHRZ1 NN O
. . O

Cell-free NN O
degradation NN O
assays NNS O
revealed VBD O
that IN O
the DT O
stability NN B-MPA
of IN O
OsPRI1 NNP O
decreased VBD O
in IN O
wild JJ O
type NN O
roots NNS O
, , O
but CC O
increased VBD B-PosReg
in IN O
the DT O
hrz1-2 VB B-Gene
mutant NN B-Var
, , O
suggesting VBG O
OsHRZ1 NN O
is VBZ O
responsible JJ O
for IN O
the DT O
instability NN O
of IN O
OsPRI1 NNP O
. . O

The DT O
hrz1-2 JJ O
seedlings NNS O
were VBD O
insensitive JJ O
to IN O
Fe-deficient NNP O
conditions NNS O
. . O

When WRB O
the DT O
pri1-1 NN B-Gene
mutation NN B-Var
was VBD O
introduced VBN B-Interaction
into IN O
hrz1-2 NNP B-Gene
mutants NNS B-Var
, , O
the DT O
pri1hrz1 NNP O
double JJ O
mutant NN O
was VBD O
more RBR B-PosReg
sensitive JJ B-MPA
to IN I-MPA
Fe NNP I-MPA
deficiency NN I-MPA
Loss-of-function NN B-NegReg
but CC O
not RB O
dominant-negative JJ O
intragenic JJ O
IKZF1 NN B-Gene
deletions NNS B-Var
are VBP O
associated VBN O
with IN O
an DT O
adverse JJ O
prognosis NN O
in IN O
adult NN O
BCR-ABL-negative NNP O
acute JJ B-Disease
lymphoblastic JJ I-Disease
leukemia NN I-Disease
. . O

Genetic JJ O
alterations NNS O
of IN O
the DT O
transcription NN O
factor NN O
IKZF1 NN O
( -LRB- O
" `` O
IKAROS NNP O
" '' O
) -RRB- O
are VBP O
detected VBN O
in IN O
around IN O
15-30 CD O
% NN O
of IN O
cases NNS O
of IN O
BCR-ABL-negative NNP O
B-cell NN O
precursor NN O
acute JJ O
lymphoblastic JJ O
leukemia NN O
( -LRB- O
ALL DT O
) -RRB- O
. . O

Different JJ O
types NNS O
of IN O
intragenic JJ O
deletions NNS B-Var
have VBP O
been VBN O
observed VBN O
, , O
resulting VBG O
in IN O
a DT O
functionally RB B-MPA
inactivated VBN I-MPA
allele NN I-MPA
( -LRB- O
" `` O
loss-of-function NN B-NegReg
" '' O
) -RRB- O
or CC O
in IN O
" `` O
dominant-negative JJ B-NegReg
" '' O
isoforms NNS B-MPA
. . O

The DT O
prognostic JJ O
impact NN O
of IN O
these DT O
alterations NNS O
especially RB O
in IN O
adult NN O
acute JJ O
lymphoblastic JJ O
leukemia NN O
is VBZ O
not RB O
well RB O
defined VBN O
. . O

We PRP O
analyzed VBD O
482 CD O
well-characterized RB O
cases NNS O
of IN O
adult NN O
BCR-ABL-negative NNP O
B-precursor NN O
acute JJ O
lymphoblastic JJ O
leukemia NN O
uniformly RB O
treated VBN O
in IN O
the DT O
framework NN O
of IN O
the DT O
GMALL NNP O
studies NNS O
and CC O
detected VBD O
IKZF1 NN O
alterations NNS O
in IN O
128 CD O
cases NNS O
( -LRB- O
27 CD O
% NN O
) -RRB- O
. . O

In IN O
20 CD O
% NN O
, , O
the DT O
IKZF1 NN O
alteration NN O
was VBD O
present JJ O
in IN O
a DT O
large JJ O
fraction NN O
of IN O
leukemic JJ O
cells NNS O
( -LRB- O
" `` O
high JJ O
deletion NN O
load NN O
" '' O
) -RRB- O
while IN O
in IN O
7 CD O
% NN O
it PRP O
was VBD O
detected VBN O
only RB O
in IN O
small JJ O
subclones NNS O
( -LRB- O
" `` O
low JJ O
deletion NN O
load NN O
" '' O
) -RRB- O
. . O

Some DT O
patients NNS O
showed VBD O
more JJR O
than IN O
one CD O
IKZF1 NN O
alteration NN O
( -LRB- O
8 CD O
% NN O
) -RRB- O
. . O

Patients NNS O
exhibiting VBG O
a DT O
loss-of-function NN O
isoform NN O
with IN O
high JJ B-Var
deletion NN I-Var
load NN I-Var
had VBD O
a DT O
shorter JJR B-NegReg
overall JJ B-MPA
survival NN I-MPA
